Canadian Intellectual Property Office

Office de la Propri,t, Intellectuelle du Canada

(11) CA 2 478 205

(13) A1

An Agency of Industry Canada

Un organisme d'Industrie Canada

12.09.2003 (43) 12.09.2003

(12)

(30)

(21) 2 478 205

(51) Int. Cl. 7:

C12N 15/09, C12P 21/02

(22) 06.03.2003

(85) 03.09.2004

(86) PCT/JP03/002675 . WO03/074699

2002-60374 JP 06.03.2002 2002-268726 JP 13.09.2002

Tsukuba-shi 305-8602, IBARAKI, XX (JP).

(87)

TAMURA, TOSHIKI (JP).

HIRAMATSU, SHINGO (JP). TANAKA, TAKASHI (JP). YAMADA, KATSUSHIGE (JP).

(74)

SMART & BIGGAR

(71)TORAY INDUSTRIES, INC., 2-1 Nihonbashi-Muromachi 2-chome Chuo-ku 103-8666, TOKYO, XX (JP). NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES, 1-2, Kannondai 2-chome,

- PROCEDE DE PRODUCTION DE PROTEINE PHYSIOLOGIQUEMENT ACTIVE UTILISANT UN VER A SOIE (54)GENETIQUEMENT MODIFIE
- PROCESS FOR PRODUCING PHYSIOLOGICALLY ACTIVE PROTEIN USING GENETICALLY MODIFIED (54)SILKWORM

(57)

It is intended to provide a genetic engineering material for insects whereby a target protein can be easily purified without resort to a recombinant baculovirus and a process for producing a foreign protein with the use of this genetic engineering material. A genetically modified silk worm is obtained by transferring a foreign protein gene (for example, a cytokine gene) ligated to a promoter functioning in the silk gland into silkworm chromosome. Then the foreign protein (for example, cytokine) is extracted and purified from the silk gland or cocoon of the silkworm or its offspring. By transferring a gene cassette for expression wherein the 5~-terminal DNA sequence of fibroin H- chain gene is fused with the 3~terminal DNA sequence of a foreign protein gene into silk gland cells or the like, the foreign protein can be produced in a large amount both inside and outside the silk gland cells as well as in silk yarn and cocoon.

*

Office de la Propriété Intellectuelle du Canada

Un organisme d'Industrie Canada Canadian Intellectual Property Office

An agency of Industry Canada CA 2478205 A1 2003/09/12

(21) 2 478 205

(12) DEMANDE DE BREVET CANADIEN CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2003/03/06

(87) Date publication PCT/PCT Publication Date: 2003/09/12

(85) Entrée phase nationale/National Entry: 2004/09/03

(86) N° demande PCT/PCT Application No.: JP 2003/002675

(87) N° publication PCT/PCT Publication No.: 2003/074699

(30) Priorités/Priorities: 2002/03/06 (2002-60374) JP; 2002/09/13 (2002-268726) JP

(51) Cl.Int.7/Int.Cl.7 C12N 15/09, C12P 21/02

(71) Demandeurs/Applicants: TORAY INDUSTRIES, INC.; JP; NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES, JP

(72) Inventeurs/Inventors: HIRAMATSU, SHINGO, JP; TANAKA, TAKASHI, JP; YAMADA, KATSUSHIGE, JP; TAMURA, TOSHIKI, JP


(74) Agent: SMART & BIGGAR

(54) Titre : PROCEDE DE PRODUCTION DE PROTEINE PHYSIOLOGIQUEMENT ACTIVE UTILISANT UN VER A SOIE GENETIQUEMENT MODIFIE

(54) Title: PROCESS FOR PRODUCING PHYSIOLOGICALLY ACTIVE PROTEIN USING GENETICALLY MODIFIED SILKWORM

(57) Abrégé/Abstract:

It is intended to provide a genetic engineering material for insects whereby a target protein can be easily purified without resort to a recombinant baculovirus and a process for producing a foreign protein with the use of this genetic engineering material. A genetically modified silk worm is obtained by transferring a foreign protein gene (for example, a cytokine gene) ligated to a promoter functioning in the silk gland into silkworm chromosome. Then the foreign protein (for example, cytokine) is extracted and purified from the silk gland or cocoon of the silkworm or its offspring. By transferring a gene cassette for expression wherein the 5"-terminal DNA sequence of fibroin H-chain gene is fused with the 3"-terminal DNA sequence of a foreign protein gene into silk gland cells or the like, the foreign protein can be produced in a large amount both inside and outside the silk gland cells as well as in silk yarn and cocoon.



gc.ca



- 60 -

ABSTRACT

The present invention provides a genetic engineering material for insects that enables a target protein to be purified easily, without requiring the use of recombinant baculovirus, while simultaneously providing a process for producing exogenous protein using that genetic engineering material. A gene recombinant silkworm is obtained by inserting an exogenous protein gene such as a cytokine gene coupled to a promoter that functions in silk glands into a silkworm chromosome. An exogenous protein such as a cytokine is then extracted and purified from the silk glands or cocoon of that silkworm or its offspring. A large amount of exogenous protein can be produced within silk gland cells, outside silk gland cells or in silk thread or a cocoon by inserting an expression gene cassette, in which the DNA sequence of the 3' terminal portion and the DNA sequence of the 5' terminal portion of fibroin H chain gene are fused to the exogenous protein gene, into silk gland cells and so forth.

5

10

15

- 1 -

DESCRIPTION

PRODUCTION OF PHYSIOLOGICALLY ACTIVE PROTEINS USING GENE RECOMBINANT SILKWORMS

5

10

15

20

25

30

Technical Field

The present invention relates to a process for producing a recombinant cytokine using a silkworm incorporating a cytokine gene in its chromosomes. In addition, the present invention relates to a gene recombinant silkworm having the property of producing a recombinant cytokine in a silk gland or cocoon and silk thread, and a vector for inserting an exogenous gene into silkworm chromosomes for producing the recombinant silkworm. In addition, the present invention also relates to a process for producing exogenous protein using insect cells, insect tissue or insects to which a gene has been inserted using the aforementioned vector. Moreover, the present invention relates to silk thread containing an exogenous protein produced by a recombinant silkworm obtained in the present invention.

Background Art

The production of exogenous proteins using gene recombination technology is used in various industries. The hosts used for their production consist mainly of E. coli, yeast, animal cells, plant cells and insect cells. However, a host has yet to be developed that is capable of efficiently producing all kinds of exogenous proteins and, as it is necessary to construct a production system for each target protein, a technical breakthrough is being sought in technology for producing exogenous proteins in individual hosts.

Systems using bacteria like *E. coli* or yeast have problems with posttranslational modification, and in some cases these systems are unable to synthesize proteins in a form that allows them to function adequately. In

BNSDOCID: <CA

addition, although animal cells allow proteins to be synthesized in a functional form, it is typically difficult to grow these cells and the production volume is low thereby making this uneconomical.

On the other hand, in the production of gene recombinant proteins using insects or insect cells, useful proteins having enzymatic or physiological activity can be produced comparatively inexpensively and modifications can be obtained, following protein translation, that resemble those in animals. More specifically, a method in which a baculovirus incorporated a recombinant exogenous gene is infected into insects or insect cells allows the exogenous protein to be produced comparatively inexpensively, and physiologically active proteins are known that have been commercialized as pharmaceuticals (Japanese Unexamined Patent Publication Nos. 61-9288 and 61-9297).

In the case of the production of cytokines, which are physiologically active substances having immunoregulatory functions and which are attracting attention in pharmaceutical applications, methods are disclosed in Japanese Unexamined Patent Publication Nos. 3-139276 and 9-234085 in which silkworms are inoculated with BmNPV containing a feline interferon- ω gene and a canine interferon- γ gene, respectively. In addition, a process for producing human collagen using insect cells infected with baculovirus is known as an example of the production of a protein other than interferon using insects (Japanese Unexamined Patent Publication No. 8-23979).

However, as technologies for producing recombinant proteins using insects or insect cells of the prior art use a recombinant virus to incorporate an exogenous gene, there is the problem of the need for deactivation or containment of recombinant virus from the viewpoint of safety. In addition, in methods in which a recombinant

5

10

15

20

25

30

virus is inoculated into a silkworm, as the inoculation of the recombinant virus is troublesome task and the target exogenous protein is produced in silkworm hemolymph, it is necessary to purify the target recombinant protein from the large amount of contaminating proteins originating in the body fluids of the silkworm. Consequently, there was the problem of it being difficult to obtain a highly pure recombinant protein.

On the other hand, attempts have been made in recent years to recombine exogenous genes into insect chromosomes, and a method has been developed that uses homologous recombination to introduce and express in silkworm chromosomes a fused gene in which jellyfish green fluorescence protein gene was coupled to silkworm fibroin L chain gene using DNA of Autographa californica nuclear polyhedrosis virus (ACNPV), which is a type of nuclear polyhedrosis virus (Genes Dev., 13, 511-516, 1999), and a silkworm containing human collagen gene and a production process have been disclosed that utilize this technology (Japanese Unexamined Patent Publication No. 2001- 161214). Recently, research has been conducted on a method for expressing a protein encoded by an exogenous gene by stably introducing that exogenous gene into silkworm chromosomes using piggyBac, which is a transposon originating in a lepidopteron, using the jellyfish green fluorescence protein as a model, and the gene has been confirmed to be stably propagated to offspring by mating (Nature Biotechnology, 18, 81-84, 2000).

However, in the aforementioned method for inserting an exogenous protein gene into insect chromosomes using AcNPV, as a recombinant baculovirus (AcNPV) is used, there is still the problem of having to deactivate and contain the recombinant virus. In the example that used the piggyBac transposon, as the amount of green fluorescence protein produced is inadequate and as it is

5

10

15

20

25

30

also produced throughout the silkworm, sophisticated purification technology is required to recover the expressed recombinant green fluorescence protein in a highly pure form, thereby resulting in the method being uneconomical. In addition, the amount of recombinant protein produced is inadequate and extremely low.

Namely, in this technology for producing an exogenous protein using insect cells as a host, there are several problems such as the need to deactivate and contain the recombinant baculovirus, the difficulty in purifying the target protein from body fluid in which a large amount of contaminating proteins are present, as in the case of using silkworms, and the expressed amount of the target protein being low.

There are no known examples, thus far, of expressing a target protein by inserting a gene that encodes a physiologically active protein such as a cytokine gene into silkworm chromosomes. In addition, there are also no examples of having recovered a recombinant cytokine from a site, other than silkworm body fluid, such as a silk gland or silk thread secreted by silkworms, and confirming the physiological activity of the resulting cytokine. In addition, there are also no precedents regarding a silkworm capable of inheriting such properties. In addition, there are no examples of having produced a large amount of recombinant protein in silk thread using a recombinant silkworm produced using a transposon.

30

35

5

10

15

20

25

DISCLOSURE OF THE INVENTION

Although extensive research has been conducted on technologies for producing recombinant proteins using insects, there are problems such as the need to deactivate and contain the recombinant baculovirus in which the exogenous protein gene has been incorporated, or the need to take a lot of time and labor associated with inoculating the recombinant virus. In addition, the

production of exogenous protein in silkworms using recombinant baculovirus had the problem of it being difficult to extract and purify the target protein from body fluid containing large amounts of contaminating proteins.

Although studies have been conducted on technologies, for producing recombinant proteins, in which an exogenous protein gene has been inserted into silkworm chromosomes, these have problems consisting of the small amount of target exogenous protein produced and the difficulty in purifying the target protein from silkworm body fluid.

In consideration of these circumstances, the object of the present invention is to provide a genetic engineering material for insects that does not require the use of recombinant baculovirus and enables a target protein having physiological activity to be purified easily, while simultaneously providing a process for producing exogenous protein using that genetic engineering material.

As a result of extensive studies, the inventors of the present invention found that, by inserting a DNA sequence having a structure in which a gene that encodes a target protein is coupled downstream from a promoter specifically expressed in silkworm silk glands into silkworm chromosomes using DNA originating in a transposon, the target protein is produced in the silk glands, or the cocoon and the silk thread, in a form that retains physiological activity, thereby leading to completion of the present invention. In the present invention, as the recombinant protein can be recovered from the silk glands or silk and cocoon thread without containing a large amount of contaminants, it offers the advantage of allowing the target protein to be purified easily. Moreover, as a virus like baculovirus is not used, virus deactivation is not necessary thereby allowing the recombinant protein to be produced both

5

10

15

20

25

30

easily and safely.

10

15

20

25

30

35

In addition, as a result of conducting extensive studies focusing on the fact that the silkworm silk glands, and particularly the posterior silk gland, produces a large amount of fibroin that accounts for 70 to 80% of silk protein, and that the fibroin is secreted by the silk gland cells, the inventors of the present invention found that the amount of exogenous protein produced is increased considerably by inserting into silk gland cells a gene cassette in which the 5' terminal of an exogenous protein gene is coupled to the 3' terminal of a fibroin H chain gene 5' terminal portion containing a first intron of fibroin H chain gene downstream from a promoter expressed in the silk glands so that the amino acid frames are continuous. In addition, it was also found that a large amount of exogenous protein is secreted and produced by silk gland cells when a fused gene in which the 3' terminal portion of fibroin H chain gene is coupled to the 3' side of an exogenous protein gene, so that the amino acid frames are continuous, is expressed under the control of a promoter expressed in silk glands. In addition, it was also found that a recombinant silkworm produces a large amount of a target protein in its silk threads when a gene cassette was produced in which a DNA sequence of the 5' terminal portion containing a first intron of fibroin H chain gene on the 5' side of an exogenous protein gene, and a DNA sequence of the 3' terminal portion of fibroin H chain gene on the 3' side, were respectively designed so that their amino acid frames were continuous, followed by producing a recombinant silkworm in which that gene cassette was inserted into its chromosomes.

The inventors of the present invention succeeded in producing a large amount of exogenous protein in silk gland cells, outside silk gland cells and in silk thread by inserting into silk gland cells and so forth an expression gene cassette in which the DNA sequence of the

5' terminal portion and the DNA sequence of the 3' portion of fibroin H chain gene were fused to an exogenous protein gene, and were able to establish an exogenous protein production technology that facilitates purification by producing an exogenous protein using silk glands instead of using a recombinant baculovirus.

Namely, the present invention relates to a process for producing a recombinant cytokine comprising producing a gene recombinant silkworm that incorporates a cytokine gene in its chromosomes, and recovering the cytokine from the silk glands or cocoon and silk thread. Moreover, the present invention also relates to a gene recombinant silkworm in which a cytokine gene is incorporated, and a gene recombinant vector used to insert the cytokine gene into the silkworm.

Moreover, the present invention relates to a genetic engineering material, such as the gene cassette or vector described below, capable of being used for exogenous protein production in insects, a transformant, a process for producing exogenous protein using that transformant, and silk thread containing exogenous protein.

Thus, the present invention provides 1) a gene cassette for expressing an exogenous protein comprising (1) a promoter expressed in silk glands, and (2) a gene coupled downstream from (1) in which the 5' terminal portion of fibroin H chain gene is fused to the 5' side of an exogenous protein structural gene.

Moreover, the present invention provides 2) a gene cassette for expressing an exogenous protein comprising (1) a promoter expressed in silk glands, and (2) a gene coupled downstream from (1) in which the 3' terminal portion of fibroin H chain gene is fused to the 3' side of an exogenous protein structural gene not containing a stop codon. Alternatively, the present invention provides a gene cassette for expressing an exogenous protein comprising (1) a promoter expressed in silk glands, and (2) a gene coupled downstream from (1) in

5

10

15

20

25

30

which an exogenous protein structural gene is fused to the 3' side of the 3' terminal portion of fibroin H chain gene.

Moreover, the present invention provides 3) a gene cassette for expressing an exogenous protein comprising (1) a promoter expressed in silk glands, and (2) a gene coupled downstream from (1) in which the 5' terminal portion of fibroin H chain gene is fused to the 5' side of an exogenous protein structural gene not containing a stop codon, and the 3' terminal portion of fibroin H chain gene is fused to the 3' side of the structural gene.

In addition, the present invention provides 4) an expression vector for insect cells containing a gene cassette for expressing an exogenous protein according to any of the aforementioned 1) through 3).

Moreover, the present invention provides 5) a process for producing exogenous protein comprising inserting an expression vector for insect cells according to the aforementioned 4) into insect cells.

Moreover, the present invention provides 6) a process for producing exogenous protein comprising producing a recombinant silkworm in which a gene cassette for expressing an exogenous protein according to any of the aforementioned 1) through 3) is incorporated in its chromosomes, and after producing the exogenous protein in the silk glands or silk thread of the resulting recombinant silkworm, recovering the exogenous protein from the silk glands or silk thread.

In addition, the present invention provides 7) a recombinant silkworm in which a gene cassette for expressing an exogenous protein according to any of the aforementioned 1) through 3) is incorporated in its chromosomes, and has the ability to produce exogenous protein in its silk glands or silk thread.

Moreover, the present invention provides 8) a silk thread containing an exogenous protein produced by the

5

10

15

20

25

- 30

silkworm according to the aforementioned 7).

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a drawing showing a restriction map of gene insertion vector pigSIB.

Fig. 2 is a drawing showing a restriction map of gene insertion vector pigFIB.

Fig. 3 is a drawing showing a restriction map of plasmid pHA3PIG having a transposase.

10 Fig. 4 is a drawing showing the results of treating the genomic DNA of 11 silkworms (G1) obtained from the positive moth groups of Table 1 with EcoRV and XmnI, followed by performing Southern blotting analysis using a feline interferon— ω gene as a probe.

Fig. 5 is a drawing showing the antiviral activity of a silk thread extract of a recombinant silkworm into which was inserted feline interferon- ω gene coupled to fibroin H chain promoter. The sample in the dyed lane is shown to have activity.

Fig. 6 is a drawing showing the results of treating silkworm silk gland genomic DNA obtained from the positive moth groups of Table 3 (3 moth groups from Experiment 1 and 2 moth groups from Experiment 2) with EcoRI or BglII followed by performing Southern blotting analysis using feline interferon—ω gene as a probe.

Fig. 7 is a drawing of the detection of expression of feline interferon mRNA in a middle silk thread of a gene recombinant silkworm by RT-PCR.

Fig. 8 is a drawing showing the antiviral activity of a middle silk gland extract and a cocoon and silk thread extract of a recombinant silkworm into which was inserted feline interferon— ω gene coupled to a sericin promoter. The sample in the dyed lane is shown to have activity.

Fig. 9 is a drawing showing the procedure for producing a construct for gene insertion containing a P-

15

IC-A gene cassette (first half).

Fig. 10 is a drawing showing the procedure for producing a construct for gene insertion containing a P-IC-A gene cassette (second half).

Fig. 11 is a drawing showing the procedure for producing a construct for gene insertion containing an HP-IC-HA gene cassette (first half).

Fig. 12 is a drawing showing the procedure for producing a construct for gene insertion containing an HP-IC-HA gene cassette (second half).

Fig. 13 is a drawing showing the procedure for producing a construct for gene insertion containing an HUP-IC-HA gene cassette (first half).

Fig. 14 is a drawing showing the procedure for producing a construct for gene insertion containing an HUP-IC-HA gene cassette (second half).

Fig. 15 is a drawing showing the procedure for producing a construct for gene insertion containing an HP-IC-A gene cassette (first half).

Fig. 16 is a drawing showing the procedure for producing a construct for gene insertion containing an HP-IC-A gene cassette (second half).

Fig. 17 is a drawing of the analysis of the expression of β -galactosidase in cultured silkworm silk glands by Western analysis. The first exon, first intron and second exon regions of fibroin H chain gene were clearly determined to play an important role in synthesis or gene expression of proteins within cells. In addition, secretion outside the cells was also confirmed.

Fig. 18 is a drawing of the analysis of the expression of recombinant protein in silkworm silk gland tissue by Western analysis. The first exon, first intron and second exon regions of fibroin H chain gene were reconfirmed to play an important role in dramatically improving the expression of recombinant protein in silkworm posterior silk gland cells. In addition, a gene region that improves the amount of protein produced was

BNSDOCID: <CA_____2478205A1_I_>

10

15

20

25

30

found in a roughly 5.5 kbp upstream region from the fibroin promoter.

Fig. 19 is a drawing of the analysis of the production of recombinant protein in silk thread by Western analysis. The 3' terminal portion of fibroin H chain gene was determined to play an important role in secretion of protein synthesized within silk gland cells to silk thread. In addition, a gene region that improves the amount of protein produced was reconfirmed in the roughly 5.5 kbp upstream region from the fibroin promoter.

BEST MODE FOR CARRYING OUT THE INVENTION

Cytokines are proteins produced by various cells that have immunoregulatory activity, antiviral activity and blood cell growth activity on hematopoietic cells and immunocytes. Their activity is demonstrated as a result of forming a precise higher order structure and bonding to specific receptors on the cell membrane. They have previously been applied clinically to humans and animals based on the characteristics of their activity.

Although there are no particular limitations on the cytokines of the present invention, they should be cytokines for which their physiological activity is maintained when expressed in silkworms, examples of which include physiologically active substances having immunoregulatory activity, antiviral activity or blood cell growth activity and so forth such as human interferon- α , β and γ (J. Interferon Res. 5, 521-526, 1985; Nucleic Acids Res. 10, 2487-2501, 1982), human interleukin-12 (J. Immunol. 146, 3074-3081, 1991), human granulocyte colony stimulating factor (Nature, 319, 415-418, 1986), human erythropoietin (Nature, 313, 806-810, 1985), human thrombopoietin (Cell, 77, 1177-1124, 1994), feline interferon- ω , (Biosci. Biotech. Biochem., 56, 211-214, 1992, GenBank database registration no. E04599),

5

10

15

20

25

30

feline erythropoietin (GenBank database registration no. FDU00685), feline granulocyte colony stimulating factor (Gene, 274, 263-269, 2001), canine interferon- γ (GenBank database registration no. S41201), canine interleukin-12 (Japanese Unexamined Patent Publication No. 10-36397) and canine granulocyte colony stimulating factor (US Patent No. 5606024). Preferable examples of cytokines include interferons and colony stimulating factors, and these preferably include interferon- α , β , γ , ω and τ along with colony stimulating factor, erythropoietin and thrombopoietin. More preferable examples of cytokines include feline interferon- ω , feline granulocyte colony stimulating factor and human interferon- β .

Feline interferon- ω gene is obtained by cutting out from a plasmid extracted from, for example, *E. coli* (pFeIFN1) (Patent Microorganism Depository No. 1633). In addition, this gene can also be obtained from rBNV100 produced by co-transfecting into established silkworm cells with a recombinant plasmid produced by ligating feline interferon- ω gene to a silkworm cloning vector (T. Horiuchi, et al., Agric. Biol. Chem., 51, 1573-1580, 1987), and silkworm nuclear polyhedrosis virus.

Feline granulocyte colony stimulating factor can be obtained by stimulating CRFK cells, which are cultured cells originating in feline kidney, with LPS followed by recovering mRNA from the cells and then carrying out PCR using the cDNA obtained by reverse transcription as a template and using primers established with reference to GenBank database registration no. AB042552.

Human interferon- β gene can be acquired by cutting out from plasmid ORF-hIFN- β (Invitrogen) that encodes its cDNA.

The method for inserting a gene into silkworm chromosomes used in the present invention should enable the gene to be stably incorporated and expressed in the

10

15

20

25

30

5

10

15

20

25

30

35

chromosomes, and be stably propagated to offspring, as well, by mating. Although a method using micro-injection into silkworm eggs or a method using a gene gun can be used, a method that is used preferably consists of the micro-injection into silkworm eggs with a target gene containing vector for insertion of an exogenous gene into silkworm chromosomes and helper plasmid containing a transposon gene (Nature Biotechnology 18, 81-84, 2000) simultaneously.

The target gene is inserted into reproductive cells in a recombinant silkworm that has been hatched and grown from the micro-injected silkworm eggs. Offspring of a recombinant silkworm obtained in this manner are able to stably retain the target gene in their chromosomes. The gene recombinant silkworm obtained in the present invention can be maintained in the same manner as ordinary silkworms. Namely, up to fifth instar silkworms can be raised by incubating the eggs under normal conditions, collecting the hatched larva to artificial feed and then raising under the same conditions as ordinary silkworms.

Gene recombinant silkworms obtained in the present invention are able to pupate and produce a cocoon in the same manner as ordinary silkworms. Males and females are distinguished in the pupa stage, and after having transformed into moths, males and females mate and eggs are gathered on the following day. The eggs can be stored in the same manner as ordinary silkworm eggs. The gene recombinant silkworms of the present invention can be maintained on subsequent generations by repeating the breeding as described above, and can be increased to large numbers.

The exogenous gene insertion vector used for the purpose of inserting a cytokine gene used in the present invention into silkworm chromosomes is not subject to any particular limitations provided it is designed so as to precisely control cytokine expression. Normally, it has

a structure in which the cytokine gene is coupled to downstream from a promoter specifically expressed in the silk glands and upstream from an arbitrary poly A sequence, and has a pair of DNA sequences originating in a transposon outside these gene sequences. Moreover, a signal sequence originating in an arbitrary gene may be coupled between the cytokine gene and the promoter, and an arbitrary gene sequence may also be coupled between the cytokine gene and poly A. In addition, an artificially designed and synthesized gene sequence can also be coupled. In addition, a sequence for replication within a bacterial host, antibiotic resistance gene, fluorescence protein gene or LacZ gene and so forth can also be coupled as necessary. For example, the gene of green fluorescence protein GFP coupled downstream from a suitable promoter can be inserted at a suitable location between a pair of transposon DNA sequences. As a result, this facilitates screening for gene recombinant silkworms. In addition, this vector may also contain all or a portion of pUC9, pUC19 or other plasmids originating in E. coli.

Moreover, although there are no particular limitations on the promoter used here, and any promoter originating in any organism can be used provided its acts effectively within silkworm cells, a promoter that has been designed to specifically induce protein in silkworm silk glands is preferable. Examples of silkworm silk gland protein promoters include fibroin H chain promoter, fibroin L chain promoter, p25 promoter and sericin promoter.

Examples of other gene sequences used in addition to the promoter include signal sequences, poly A sequences and other sequences that control gene expression. These are not limited to specific gene sequences, but rather those which are suitable for expression of the target gene can be selected. Examples include sequences originating in the target protein such as signal

5

10

.15

20

25

30

5 -

10

15

20

25

30

35

sequences of cytokines such as feline interferon- ω and poly A sequences, and signal sequences and poly A sequences of insect protein contained in the silkworm serving as the host. Alternatively, other examples include sequences that have been proven to be generally effective for expressing proteins such as SV40 poly A and bovine growth hormone poly A. By changing the gene sequence of the aforementioned promoters and the other sequences coupled with the cytokine genes, the locations where they are expressed and the amounts expressed can be controlled.

In the present invention, a "gene cassette for expressing an exogenous protein" refers to a set of DNA required for a synthesis of protein encoded by the exogenous protein structural gene in the case of being inserted into insect cells. This gene cassette for expressing an exogenous protein contains an exogenous protein structural gene and a promoter that promotes expression of that gene. Normally, it also contains a terminator and poly A addition region, and preferably contains a promoter, exogenous protein structural gene, terminator and poly A addition region. Moreover, it may also contain a secretion signal gene coupled between the promoter and the exogenous protein structural gene. arbitrary gene sequence may also be coupled between the poly A addition sequence and the exogenous protein structural gene. In addition, an artificially designed and synthesized gene sequence can also be coupled.

In addition, a "gene cassette for inserting a gene" refers to a gene cassette for expressing an exogenous gene having an inverted repetitive sequence of a pair of piggyBac transposons on both sides, and consisting of a set of DNA inserted into insect cell chromosomes through the action of the piggyBac transposons.

There are no particular limitations on the method used to acquire DNA used in the present invention. Examples of such methods include a method in which a

required gene region is amplified and acquired using a polymerase chain reaction (PCR) based on known genetic information, and a method in which a genome library or cDNA library is screened using homology as an indicator based on known genetic information. In the present invention, these genes include variants resulting from genetic polymorphism and artificial mutation treatment using mutagens and so forth. Genetic polymorphism refers to that in which a portion of the base sequence of a gene is altered by a sudden spontaneous mutation in the gene.

Although there are no particular limitations on the promoter in the gene cassette for expressing an exogenous protein, that having a high level of activity that promotes expression of an exogenous protein gene is preferable. Although examples include the promoter of drosophila heat shock protein gene described in Japanese Unexamined Patent Publication No. 6-261770 and the promoter of silkworm actin gene (Nature Biotechnology 18, 81-84, 2000), promoters having a high level of promoting activity in silkworm silk gland cells are preferable, examples of which include the promoters of fibroin H chain gene (base numbers 255-574 of GenBank registration no. V00094), fibroin L chain gene (Gene, 100, 151-158; GenBank registration no. M76430) and sericin gene (base numbers 599-1656 of GenBank registration no. AB007831).

"Exogenous protein structural gene" refers to a gene not possessed by host cells in which a gene is to be expressed, and which encodes a protein not inherently produced by the host cells. Although there are no particular limitations thereon, in consideration of industrial value, examples include genes of proteins that are produced by humans or mammals such as genes of growth hormones, cytokines, growth factors and cell structural proteins. In addition, genes of enzymes and various proteins produced by microbes, plants or insects are also included in the scope of the present invention.

In the gene cassette for expressing an exogenous

5

10

15

20

25

30

5

10

15

20

25

30

35

protein in the present invention, the 5' terminal portion of fibroin H chain gene is a DNA sequence having action that enhances expression of exogenous protein gene by a promoter, and contains a first exon of fibroin H chain gene, all or a portion of a first intron, and a portion of a second exon. By fusing the 5' side of an exogenous protein structural gene to the 3' side of this second exon so that the amino acid reading frame is contiguous, the amount of exogenous protein produced can be improved. However, since surplus amino acid residues are added to the N terminal side of the target exogenous protein if the second exon portion is too long, there are cases in which the structure or activity of the target exogenous protein is lost. Consequently, it is necessary that the second exon portion have a suitable length according to the purpose. In many cases, favorable results can be obtained by making the second exon portion to extend to immediately after or up to several amino acid residues from the secretion signal gene of fibroin H chain gene. In addition, as the region upstream from the 5' side of fibroin H chain gene promoter, namely a roughly 5.5 kbp upstream region, is considered to be the region that enhances promoter activity, adding this region can be expected to increase the amount of target protein expressed.

In the case of producing an exogenous protein in silkworm silk glands, the 3' terminal portion of fibroin H chain gene is a DNA sequence having the effect of causing secretion of a large amount of exogenous protein outside the silk gland cells. A recombinant silkworm in which a gene cassette for expressing an exogenous protein, in which the 3' terminal portion of fibroin H chain gene serving as the signal for secreting into silk thread is fused to the 3' side, is inserted into its chromosomes is able to produce exogenous protein in its silk thread. In addition, the 3' terminal portion of fibroin H chain gene may be present upstream or

downstream from the exogenous protein gene or within the exogenous protein gene.

In the case at least one cysteine residue is present in this portion and the 3' terminal of fibroin H chain gene is used as is, the cysteine residue is located at the 20th residue from the carboxyl terminal of the fibroin H chain gene. This cysteine fulfills the role of bonding to fibroin L chain by a disulfide bond. are no particular limitations on the length of the DNA sequence of the 3' terminal portion of fibroin H chain gene provided it does not inhibit formation of the disulfide bond with fibroin L chain. As a repetitive DNA sequence continues from about 100 or more bases upstream from the 3' terminal of fibroin H chain, cleaving the DNA sequence of this upstream portion to an arbitrary length is difficult with a restriction endonuclease. consideration of the ease of genetic engineering techniques, roughly 100 base pairs on the 3' portion where the repetitive DNA sequence of fibroin H chain gene ends can be preferably used for the 3' terminal portion of fibroin H chain. In addition, as a large number of amino acids originating in the carboxyl terminal of fibroin H chain protein bond to the carboxyl terminal or amino terminal of the exogenous protein if the 3' terminal portion of fibroin H chain gene is excessively long, there are cases in which the structure or activity of the target exogenous protein is lost. Thus, there are cases in which it is necessary to make the DNA sequence of the 3' terminal portion of fibroin H chain gene as short as possible depending on the target protein.

Although there are no particular limitations on the poly A region, a poly A region of a protein gene expressed in large amounts in silk glands, such as fibroin H chain, fibroin L chain or sericin, can be used preferably.

A vector in the present invention refers to that having a cyclic or linear DNA structure. A vector

5

10

15

20

25

30

capable of replicating in *E. coli* and having a cyclic DNA structure is particularly preferable. This vector can also incorporate a marker gene such as an antibiotic resistance gene or jellyfish green fluorescence protein gene for the purpose of facilitating selection of transformants.

Although there are no particular limitations on the insect cells used in the present invention, they are preferably lepidopteron cells, more preferably Bombyx mori cells, and even more preferably silkworm silk gland cells or cells contained in Bombyx mori eggs. In the case of silk gland cells, posterior silk gland cells of fifth instar silkworm larva are preferable because there is active synthesis of fibroin protein and they are easily handled.

10

15

20

25

30

35

There are no particular limitations on the method used to incorporate a gene cassette for expression of exogenous protein and a vector into the insect cells. Although the calcium phosphate method, methods using electroporation, methods using liposomes, methods using a gene gun and methods using micro-injection can be used for incorporation into cultured insect cells, in the case of incorporating into silkworm silk gland cells, for example, a gene can be easily incorporated into posterior silk gland tissue removed from the body of a fifth instar silkworm larvae using a gene gun.

Gene incorporation into the posterior silk gland using a gene gun can be carried out by, for example, bombarding gold particles coated with a vector containing a gene cassette for expressing exogenous protein into a posterior silk gland immobilized on an agar plate and so forth using a particle gun (Bio-Rad, Model No. PDS-1000/He) at an He gas pressure of 1,100 to 1,800 psi.

In the case of incorporating a gene into cells contained in eggs of Bombyx mori, a method using micro-injection is preferable. Here, in the case of performing micro-injection into eggs, it is not necessary to micro-

inject into the cells of the eggs directly, but rather a gene can be incorporated by simply micro-injecting into the eggs.

A recombinant silkworm containing the "gene cassette for expressing an exogenous protein" of the present invention in its chromosomes can be acquired by microinjecting a vector having a "gene cassette for inserting a gene" into the eggs of Bombyx mori. For example, a first generation (G1) silkworm is obtained by simultaneously micro-injecting a vector having a "gene cassette for inserting a gene" and a plasmid in which a piggyBac transposase gene is arranged under the control of silkworm actin promoter into Bombyx mori eggs according to the method of Tamara, et al. (Nature Biotechnology 18, 81-84, 2000), followed by breeding the hatched larva and crossing the resulting adult insects (G0) within the same group. Recombinant silkworms normally appear at a frequency of 1 to 2% among this G1 generation.

Selection of recombinant silkworms can be carried by PCR using primers designed based on the exogenous protein gene sequence after isolating DNA from the G1 generation silkworm tissue. Alternatively, recombinant silkworms can be easily selected by inserting a gene encoding green fluorescence protein coupled downstream from a promoter capable of being expressed in silkworm cells into a "gene cassette for inserting a gene" in advance, and then selecting those individuals that emit green fluorescence under ultraviolet light among G1 generation silkworms at first instar stage.

In addition, in the case of the micro-injection of a vector having a "gene cassette for inserting a gene" into Bombyx mori eggs for the purpose of acquiring recombinant silkworms containing a "gene cassette for expressing an exogenous protein" in their chromosomes, recombinant silkworms can be acquired in the same manner as described above by simultaneously micro-injecting a piggyBac

5

10

15

20

- 25

30

transposase protein.

5

10

15

20

25

30

35

A piggyBac transposon refers to a transfer factor of DNA having an inverted sequences of 13 base pairs on both ends and an ORF inside of about 2.1k base pairs.

Although there are no particular limitations on the piggyBac transposon used in the present invention, examples of those that can be used include those originating in Trichoplusia ni cell line TN-368,

Autographa californica NPV (AcNPV) and Galleria mellonea NPV (GmMNPV). A piggyBac transposon having gene and DNA transfer activity can be preferably prepared using plasmids pHA3PIG and pPIGA3GFP having a portion of a piggyBac originating in Trichoplusia ni cell line TN-368 (Nature Biotechnology 18, 81-84, 2000).

The structure of the DNA sequence originating in a piggyBac is required to have a pair of inverted terminal sequences containing a TTAA sequence, and has an exogenous gene such as a cytokine gene inserted between those DNA sequences. It is more preferable to use a transposase in order to insert an exogenous gene into silkworm chromosomes using a DNA sequence originating in a transposon. For example, the frequency at which a gene is inserted into silkworm chromosomes can be improved considerably by simultaneously inserting DNA capable of expressing a piggyBac transposase to enable the transposase transcribed and translated in the silkworm cells to recognize the two pairs of inverted terminal sequences, cut out the gene fragment between them, and transfer it to silkworm chromosomes.

The gene recombinant silkworm used in the present invention refers to a silkworm which has had inserted into its chromosomes an exogenous protein gene, and after treating the silkworm chromosomal DNA with restriction endonuclease in accordance with ordinary methods, yields a positive signal when subjected to Southern blotting using the exogenous protein gene labeled in accordance with ordinary methods as a probe. There are no

particular limitations on the gene locus on the chromosome into which a cytokine gene has been inserted provided it is a site that does not inhibit silkworm development, differentiation and growth. The recombinant silkworm has the ability to produce exogenous protein in its silk gland cells, silk gland lumen and silk thread. In addition, the recombinant silkworm is able to develop and mate normally, stably retain the inserted exogenous protein gene, and transmit that gene to its offspring. Thus, the amount of exogenous protein produced can easily be increased by increasing the number of recombinant silkworms through crossing. Crossing between transgenic silkworm strain and non-transgenic strain can increase the amount of the produced exogenous protein. case, it is necessary to cross the silkworms while suitably selecting those silkworms into which the target exogenous protein gene has been inserted. In this case, offspring that have inherited the gene of the recombinant silkworm can be easily evaluated by analyzing a marker gene used to select the recombinant silkworms or the presence or structure of the exogenous protein gene by PCR or Southern blotting and so forth using cell DNA obtained from an arbitrary tissue.

Insect cells and silkworm silk glands containing the gene cassette for expression of an exogenous protein of the present invention can produce exogenous protein in culture supernatant or their cells by respectively culturing in culture liquid suitable for their culturing. For example, BmN cells, which are silkworm ovary cells that have been inserted with the expression gene cassette of the present invention, produce a target exogenous protein after 3 or 4 days of culturing by culturing at 27°C in TC-100 medium (PharMingen). In addition, silkworm posterior silk gland produces exogenous protein by culturing at 25°C in Grace's insect medium after being excised aseptically from, for example, fifth instar larva. In the case of producing protein in silk glands,

5

10

15

20

25

30

5

10

15

20

25

30

35

it is preferable to maintain a high dissolved oxygen concentration in the medium, and culture while removing low molecular weight factors that inhibit protein synthesis that accumulate in the medium by, for example, an ultrafiltration membrane since this allows protein synthesis to proceed for a long period of time.

A silk gland inserted with an exogenous protein gene fused to the 3' terminal of fibroin H chain gene of the present invention is capable of producing a large amount of a target exogenous protein in culture supernatant. Since nearly all contaminating proteins in the silk gland culture supernatant are fibroin, the target protein can be easily purified from the silk gland culture supernatant, and as a result, a highly pure target protein can be obtained.

The recombinant silkworm obtained in the present invention can be raised in the same manner as ordinary silkworms, and is able to produce exogenous protein by raising under ordinary conditions. The amount of exogenous protein produced can be improved by optimizing the temperature, humidity and feeding conditions, etc. during the fifth instar period in particular corresponding to the target exogenous protein.

A recombinant silkworm inserted with an exogenous protein gene fused to the 3' terminal of fibroin H chain gene of the present invention is able to produce a large amount of a target exogenous protein in its cocoon. The target exogenous protein can also be easily purified and recovered from the resulting cocoon. In addition, depending on the function of the exogenous protein produced, silk thread containing the resulting exogenous protein can be used directly or in a partially processed form in various industrial applications.

Exogenous protein can be obtained from the silk gland or cocoon and silk thread of a recombinant silkworm obtained in the present invention by a suitable extraction procedure. Although there are no particular

limitations on the solvent used to extract exogenous protein from silk glands or cocoon and silk thread, an aqueous solvent system is preferable in many cases. An aqueous solution used for extraction may contain a suitable solute for promoting extraction of the exogenous protein, examples of which include inorganic acids such as phosphoric acid, organic acids such as acetic acid, citric acid and malic acid, salts such as sodium chloride, urea, guanidine hydrochloride and calcium chloride, and polar organic solvents such as ethanol, methanol, acetonitrile and acetone. In addition, there are also no particular limitations on the pH of the extraction solution, and any arbitrary pH can be used provided it does not deactivate the function of the target exogenous protein.

There are no particular limitations on the method for isolating and purifying the extracted exogenous protein, and ordinary protein purification methods can be used. For example, a target useful protein can be purified and isolated by combining chromatography using a silica gel carrier, ion exchange carrier, gel permeation carrier, chelating carrier or pigment-loaded carrier and so forth, ultrafiltration, gel permeation, dialysis, desalting by salting out or concentration and so forth using an inherently possessed function as an indicator. For example, feline interferon-ω can be recovered in the soluble fraction obtained by homogenizing silk glands or cocoon and silk thread of a silkworm into which has been inserted a feline interferon- ω gene with 20 mM phosphate buffer (pH 7.0). Moreover, the purity of the feline interferon- ω can be increased by adsorbing the resulting extract liquid onto, for example, a Blue Sepharose carrier and eluting the resulting buffer solution containing the extract liquid after washing.

Cytokines produced in this manner can be used in pharmaceutical applications as well as various

5

10

15

20

25

30

measurement and diagnostic applications in the same manner as cytokines produced with other conventional production processes. In this case, they may also be used as a mixture to which various additives have been added. In addition, the tissue or cocoon and silk thread of a silkworm in which cytokines have been expressed can also be used directly or after processing as fibers for medical or clothing use. In addition, the tissue or silk thread of a recombinant silkworm in which enzymes have been expressed can be used directly in enzyme reactions.

Examples

5

10

15

20

25

30

35

Although the following provides a more detailed explanation of the present invention by indicating its examples, the present invention is not limited to the descriptions of these examples.

Reference Example - Method for Measuring Antiviral Activity

The physiological activity of interferon was measured according to the following method as antiviral activity.

Antiviral activity was measured by the CPE method using vesicular stomatitis virus (VSV) for the virus, and using feline Fc9 cells (J.K. Yamamoto, et al.: Vet. Immunol. and Immunopathol., 11, 1-19, 1986) for the susceptive cells in the case of feline interferon- ω , or human FL cells in the case of human interferon- β . Namely, a sample diluent was added to the uppermost row of 96-well microtiter plate in which susceptive cells cultured at 37°C to confluency, and then serially diluting in two-fold increments moving towards the lower end of the plate.

After culturing for 20 to 24 hours at 37°C, VSV was added followed by additionally culturing for 16 to 20 hours at 37°C. Viable susceptive cells adhered to the microtiter plate were then stained with crystal-violet

stain containing 20% formalin, and as a result of measuring the optical absorbance at 570 nm for the amount of crystal-violet remaining on the microplate, antiviral activity was determined by comparison with a standard. Intercat (Toray) adjusted to 1000 units/ml with cell culturing medium was used for the standard for feline interferon- ω , while Feron (Toray) prepared to 1000 units/ml with cell culturing medium was used for the standard for human interferon- β . In addition, samples were used for the measurement of antiviral activity after diluting 15-fold with cell culturing medium.

Example 1 - Preparation of Bombyx mori Genomic DNA Fifth instar third day silkworms were dissected to remove posterior silk gland tissue. After washing with 1xSSC, 200 µl of DNA extraction buffer (50 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0), 100 mM NaCl) were added. After adding Proteinase K (final concentration: 20 µg/ml) and adequately grinding up the tissue with a grinder, 350 μl of DNA extraction buffer and 60 μl of 10% SDS were added followed by incubating for 2 hours at 50°C. After adding 500 µl of Tris-HCl-saturated phenol (pH 8.0) and mixing for 10 minutes, the supernatant was recovered by centrifuging for 5 minutes at 4°C and 10,000 rpm. After adding an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) to the supernatant and mixing, the resulting mixture was centrifuged. Phenol/chloroform/isoamyl alcohol was again added followed by centrifuging and recovery of the supernatant. After adding an equal volume of chloroform/isoamyl alcohol (24:1) and mixing, the mixture was centrifuged. Chloroform/isoamyl alcohol was again added to the resulting supernatant followed by centrifuging and recovery of the supernatant. 1/10 volume 3 M sodium acetate (pH 5.2) was then added to the resulting supernatant and mixed and, after additionally adding 2.5

5

10

15

20

25

30

volumes of cold ethanol and allowing it to stand undisturbed for 30 minutes at -80°C , the mixture was centrifuged for 10 minutes at 4°C and 15,000 rpm to precipitate genomic DNA. After washing the DNA precipitate with 70% ethanol, the precipitate was airdried. The precipitate was then dissolved in sterile water containing RNase to 100 $\mu\text{g/ml}$ to prepare a diluted genomic DNA solution.

Example 2 - Gene Preparation

5

10

15

20

25

30

35

The genes used were acquired by PCR by producing primers for the sequences on both ends using known sequences and using suitable DNA sources for the templates. Restriction sites were added to the ends of the primers for the subsequent gene construction procedure.

Feline interferon-ω gene (base numbers 9-593 of GenBank registration no. S62636) was acquired by PCR using two types of primers consisting of primer 3 (SEQ. ID No. 3) and primer 4 (SEQ. ID No. 4) and using baculovirus rBNV100 encoding feline interferon-ω gene for the template. rBNV100 can be produced by, for example, cutting out FeIFN gene from a plasmid extracted from E. coli (pFeIFN1) (Patent Microorganism Depository No. 1633), coupling to a silkworm cloning vector (T. Horiuchi, et al., Agric. Biol. Chem., 51, 1573-1580, 1987), and co-transfecting silkworm established cells with the recombinant plasmid produced and silkworm nuclear polyhedrosis virus DNA.

Sericin-1 gene promoter (base numbers 599-1656 of GenBank registration no. AB007831) was acquired by PCR using two types of primers consisting of primer 5 (SEQ. ID No. 5) and primer 6 (SEQ. ID No. 6) and using silkworm chromosomal DNA for the template. Fibroin H chain gene promoter (base numbers 255-574 of GenBank registration no. V00094) was acquired by PCR using two types of primers consisting of primer 7 (SEQ. ID No. 7) and primer

8 (SEQ. ID No. 8) and using silkworm chromosomal DNA for the template. Bovine growth hormone gene poly A (pcDNA3.1(+) sequence numbers 1011-1253) was acquired by PCR using two types of primers consisting of primer 9 (SEQ. ID No. 9) and primer 10 (SEQ. ID No. 10) and using plasmid pcDNA3.1(+) vector (Invitrogen) for the template.

PCR was carried out in accordance with the accompanying protocol using KODplus (Toyobo). Namely, after adding 10 ng of each template in the case of a plasmid or 100 ng in the case of chromosomal DNA, 30 pmol of each primer and 10 µl of the 10xPCR buffer provided, each reagent was added to a concentration of 1 mM MgCl₂, 0.2 mM dNTPs and 2 units of KODplus followed by bringing up to a final volume of 100 µl. The PCR components were then reacted for 30 cycles using a Perkin-Elmer DNA thermal cycler under DNA denaturation conditions of 94°C for 15 seconds, primer annealing conditions of 55°C for 30 seconds, and elongation conditions of 68°C for 30 to 60 seconds.

These reaction solutions were electrophoresed with 1 to 1.5% agarose gel, and DNA fragments consisting of a roughly 580 bp fragment in the case of feline interferon- ω gene, a roughly 1 kbp fragment in the case of sericin-1 promoter, a roughly 320 bp fragment in the case of fibroin H chain promoter, and a roughly 230 bp fragment in the case of bovine growth hormone poly A were extracted and prepared in accordance with ordinary methods. After phosphorylating these DNA fragments with polynucleotide kinase (Takara Shuzo), they were ligated to pUC19 vector subjected to dephosphorylation treatment after being cleaved with HincII by reacting overnight at 16°C using DNA Ligation Kit Ver. 2 (Takara Shuzo). were then used to transform E. coli in accordance with ordinary methods and the resulting transformants were confirmed to contain the PCR fragments by performing PCR on the resulting colonies under the same conditions as

5

10

15

20

25 -

30

previously described to prepare plasmids in which the PCR fragments were inserted according to ordinary methods. These plasmids were sequenced to confirm that the resulting fragments consisted of the base sequences of each gene.

Example 3 - Production of Plasmids for Gene Insertion

10

15

20

25

30

35

pigA3GFP (Nature Biotechnology 18, 81-84, 2000) was used for the plasmid for gene insertion. Namely, vector pigA3GFP is a vector in which after removing a region encoding transposase from plasmid p3E1.2 disclosed in US Patent No. 6218185, an A3 promoter (base numbers 1764-2595 of GenBank registration no. U49854), GFP originating in pEGFP-N1 vector (Clontech) and poly A addition sequence originating in SV40 (base numbers 659-2578 of GenBank registration no. U55762) are inserted into that portion (Nature Biotechnology 18, 81-84, 2000). expression unit of feline interferon-ω gene was inserted at the XhoI site upstream from the A3 promoter. expression units of the inserted genes consisted of a sericin-1 gene promoter-feline interferon-ω-bovine growth hormone poly A addition sequence (SEQ. ID No. 1), or a fibroin H chain gene promoter-feline interferon-ωbovine growth hormone poly A addition sequence (SEQ. ID No. 2). The following provides a detailed description of the method.

Genes were cleaved from the plasmids prepared in Example 2 using the restrictase sites preset in the primers. Namely, insert fragments were cleaved using EcoRI and SalI in the case of sericin-1 gene promoter and fibroin H chain gene promoter, SalI and XbaI in the case of feline interferon- ω , and XbaI and BamHI in the case of bovine growth hormone poly A, followed by electrophoresing with 1 to 1.5% agarose gel and extracting and purifying the fragments in accordance with ordinary methods.

200 ng of sericin-1 gene fragment, 100 ng of feline interferon- ω gene fragment, and 50 ng of bovine growth hormone poly A were mixed and reacted overnight at 16°C by adding an equal volume of DNA Ligation Kit Version 2 (Takara Shuzo). 0.5 μ l of the reaction solution was subjected to PCR using primer 11 (SEQ. ID No. 11) and primer 12 (SEQ. ID No. 12) for 2 minutes of elongation under the same conditions as Example 2. These reaction solutions were electrophoresed with 1% agarose gel, and the amplified, roughly 1.9 kb, DNA fragment (SIB fragment) was extracted and purified in accordance with ordinary methods.

Similarly, 70 ng of fibroin H chain gene promoter fragment, 100 ng of feline interferon— ω gene fragment and 50 ng of bovine growth hormone poly A were mixed and reacted overnight at 16°C by adding an equal volume of DNA Ligation Kit Version 2 (Takara Shuzo). 0.5 μ l of the reaction solution was subjected to PCR using primer 13 (SEQ. ID No. 13) and primer 12 (SEQ. ID No. 12) for 2 minutes of elongation under the same conditions as Example 1. These reaction solutions were electrophoresed with 1% agarose gel, and the amplified roughly 1.5 kb DNA fragment (FIB fragment) was extracted and purified in accordance with ordinary methods.

After digesting these fragments with XhoI, they were ligated to pigA3GFP and subjected to XhoI treatment and dephosphorylation treatment by reacting overnight at 16°C using DNA Ligation Kit Ver. 2 (Takara Shuzo). The plasmid containing the SIB fragment was designated as pigSIB (Fig. 1), and the plasmid containing the FIB fragment was designated as pigFIB (Fig. 2), and these were purified by centrifuging twice using the cesium chloride method and then used in a gene insertion experiment.

Example 4 - Production of Gene Recombinant Silkworms
(Fibroin H Chain Gene Promoter)

5

10

15

20

25

30

. 35

5

10

15

20

25

30

The aforementioned pigFIB and helper plasmid pHA3PIG (Fig. 3, Nature Biotechnology 18, 81-84, 2000) were adjusted to a concentration of 200 ng/ml each in 0.5 mM phosphate buffer (pH 7.0) and 5 mM KCl, after which 15 to 20 nl were micro-injected into silkworm eggs within 4 hours after being laid.

The larva that hatched from those silkworm eggs were raised, and the resulting adults (G0) were crossed within the same group. By observing the resulting first generation (G1) individuals with fluorescence of green fluorescence protein that had been simultaneously inserted with feline interferon— ω gene, those silkworms that contained the feline interferon— ω gene in their chromosomes were screened. The ratios of the moth groups in which silkworms containing the inserted gene were obtained are shown in Table 1. The silkworm eggs were injected twice, and gene recombinant silkworms were obtained from one moth group by the second injection. Table 1 Acquisition Status of Gene Recombinant Silkworms (Fibroin Heavy Chain Promoter)

Experiment No. of No. of No. of No. of No. of moth sibling adults Group eggs eggs groups mated positive for injected hatched moths feline interferon-ω gene 292 220 100 1215 0 250 1326 374 123

The results of Southern blotting on the gene recombinant silkworms obtained from that moth group are shown in Fig. 4. The method employed for Southern blotting consisted of extracting chromosomal DNA from the G1 generation moths, electrophoresing restrictase-treated samples, and detecting a membrane to which the DNA was transferred by chemiluminescence using the AlkPhos Direct Labeling and Detection System (Amersham-Pharmacia) using a nucleic acid probe specific for feline interferon- ω .

When 11 G1 moths were investigated, feline interferon- ω gene was confirmed to have been inserted into 10 of the silkworms.

Example 5 - Confirmation of Feline Interferon Production (Fibroin H Chain Promoter)

Since feline interferon- ω has antiviral activity, the presence of feline interferon- ω can be determined according to its activity. Silkworms (G1) of the positive moth group obtained in Example 4 were mated with wild silkworms, and the middle and posterior silk glands excised from fifth instar larva of the resulting generation (G2) were confirmed to be inserted with feline interferon- ω gene. These were then homogenized using 20 mM sodium phosphate buffer (pH 7.0), and the resulting extract was measured using an antiviral activity measuring system that used feline cells. As a result, although antiviral activity was detected for both middle silk glands and posterior silk glands from the silk gland extracts of gene-containing silkworms, activity was not detected from the silk gland extracts of wild silkworms used as the control. Those results are shown in Fig. 5.

Feline interferon- ω is thought to mainly be expressed in posterior silk glands under the control of fibroin H chain promoter. It is believed to subsequently migrate into the middle and anterior silk glands in the same manner as fibroin, and the distribution of physiological activity is considered to coincide with this. On the other hand, there was no antiviral activity detected from silkworms into which the gene was not inserted. This clearly demonstrates that feline interferon- ω protein is expressed while retaining its physiological activity in silkworms into which feline interferon- ω gene has been inserted.

Example 6 - Purification of Feline Interferon
Feline interferon was purified from the extract of

5

10

15

20

25

30

posterior silk glands excised from G2 generation, fifth instar silkworms obtained in Example 5. 1 ml of extract was passed through a HiTrap Blue Sepharose column (Amersham-Pharmacia) followed by washing the column with 10 ml of 20 mM sodium phosphate buffer (pH 7.0). Continuing, the column was eluted with 10 ml of 20 mM sodium phosphate buffer (pH 8.0)-0.5 M NaCl and then with 10 ml of 20 mM sodium phosphate buffer (pH 8.0)-1 M NaCl. The washing fraction, 0.5 M elution fraction and 1 M elution fraction were collected, desalted and concentrated to about 1 ml. The results of determining the antiviral activity and amount of protein of the extract and each purified fraction are shown in Table 2.

Table 2 Purification of Feline Interferon- ω by Blue Sepharose Chromatography

15

elution fraction 1 M NaCl

10

5

Antiviral Amt. of Specific activity protein activity (U/mg) (U/ml) (mg/ml) 523 Extracted 0.37 1401 sample 23 2.91 Blank, 8 washing fraction 1494 0.5 M NaCl 0.85 1758

elution fraction

As a result of the purification procedure, antiviral activity, namely feline interferon-ω, could be recovered in the 1 M elution fraction, and its specific activity

>6270

was roughly 10 times that of the extract.

Example 7 - Production of Recombinant Gene Silkworms
(Sericin-1 Promoter)

0.41

>15293

The aforementioned pigSIB and a helper plasmid were adjusted to a concentration of 200 ng/ml each in 0.5 mM phosphate buffer (pH 7.0) and 5 mM KCl, after which 15 to 20 nl were micro-injected into silkworm eggs within 4 hours after being laid. The larva that hatched from

those silkworm eggs were raised, and the resulting adults (G0) were crossed within the same group. Insertion of feline interferon- ω gene into the chromosomes was investigated by observing the fluorescence of green fluorescence protein from the resulting first-generation (G1) individuals. In two experiments, a gene recombinant vector containing feline interferon- ω gene coupled to sericin promoter was micro-injected into 1218 and 1375 eggs, respectively, and 12 positive moth groups each were able to be obtained (Table 3).

Table 3 Acquisition Status of Gene Recombinant Silkworms
(Sericin Promoter)

Experiment Group	No. of eggs injected	eggs	No. of adults	No. of sibling mated moths	No. of moth groups positive for feline interferon-ω gene
1	1218	500	320	158	12
2	1375	540	500	225	12

One silkworm (G1) each that was confirmed to contain the gene was selected from 3 moths groups in the first experiment and 2 moth groups in the second experiment among the resulting positive moth groups, and genomic DNA was extracted from their silk glands. After treating with EcoRI or BglII, Southern blotting analysis was performed on the DNA using feline interferon— ω gene as a probe. Those results are shown in Fig. 6. As a result, feline interferon— ω gene was confirmed to be inserted in the genomes of all silkworms. In addition, the site at which the gene was inserted into the genome was determined to be different depending on the moth group due to differences in the detected signal size.

Next, mRNA expression of feline interferon- ω gene was investigated. Seven G1 silkworms confirmed to contain feline interferon- ω gene by Southern blotting were randomly selected, their mRNA was extracted and the

5

10

15

20

25

expression of feline interferon- ω gene mRNA was investigated by RT-PCR. Isogen (Nippon Gene) and Oligodex dT-30 (Roche Diagnostics) were used for mRNA extraction and purification, the Ready-To-Go T-Primed First-Strand Kit (Amersham-Pharmacia) was used for cDNA synthesis, and the procedure was carried out according to the protocol provided with the kit. As a result of carrying out PCR under the same conditions as during the acquisition of feline interferon- ω gene of Example 2, expression of feline interferon- ω gene mRNA was

10 expression of feline interferon- ω gene mRNA was confirmed for all of the silkworms (Fig. 7).

Example 8 - Confirmation of Feline Interferon

Production in Middle Silk Glands and Cocoon and Silk

Thread

The middle silk glands were excised from three gene recombinant silkworms obtained in Example 7 and one wild silkworm followed by homogenizing using 20 mM sodium phosphate buffer (pH 7.0) and centrifuging to prepare extracts. In addition, one cocoon each from the gene recombinant silkworms and wild silkworm were extracted in the same manner. When these extracts were measured for their antiviral activity, antiviral activity was detected in the middle silk glands of all of the gene recombinant silkworms, but was not detected in the silk glands of the wild silkworm. Moreover, antiviral activity was also detected in the cocoons of the gene recombinant silkworms (Fig. 8).

On the basis of these findings, feline interferon- ω was determined to be expressed in gene recombinant silkworms while retaining its physiological activity, and that activity was determined to remain in the silk thread.

Example 9 - Production of Plasmids for Insertion of Human Interferon-β Gene

35 Production of plasmids for insertion of human

5

15

20

25

interferon- β gene was carried out according to the same method as the case of feline interferon- ω gene indicated in Examples 2 through 4.

Namely, PCR was carried out using primer 14 (SEQ. ID No. 14) and primer 15 (SEQ. ID No. 15) and using plasmid pORF-hIFN- β encoding human interferon- β gene as a template to obtain a human interferon- β gene fragment. After treating this fragment with restriction endonucleases SalI and XbaI, a plasmid was constructed that contained a gene expression sequence in which fibroin H chain gene promoter was coupled to the 5' terminal or poly A signal originating in bovine growth hormone gene was coupled to the 3' terminal (fibroin H chain promoter-human interferon- β gene-bovine growth hormone gene poly A signal (FhIB): SEQ. ID No. 16, sericin gene promoter-human interferon- β -bovine growth hormone gene poly A signal (ShIB): SEQ. ID No. 17).

The aforementioned FhIB and ShIB sequences for gene expression were then respectively cleaved from these plasmids by treating with XhoI, and coupled to pigA3GFP that had been subjected to dephosphorylation treatment after being cleaved with XhoI. The plasmid containing the FhIB fragment was designated as pigFhIB, while the plasmid that contained the ShIB fragment was designated as pigShIB. These fragments were purified by centrifuging twice according to the cesium chloride method and then used in a gene insertion experiment.

Example 10 - Production of Human Interferon-β Gene Recombinant Silkworms

Production of human interferon- β gene recombinant silkworms was carried out according to the same method used to produce feline interferon- ω gene recombinant silkworms indicated in Example 4 by using the gene insertion plasmids produced in Example 9.

5

10

15

20

25

Namely, pigFhIB and pigShIB were respectively microinjected into silkworm eggs together with helper plasmid pHA3PIG, and the resulting adults were crossed followed by screening of the next generation. When each plasmid was injected into 600 eggs, silkworms positive for green fluorescence were obtained in 7 moth groups for silkworms containing pigFhIB and in 5 moth groups for silkworms containing pigShIB, and insertion of the genes into their chromosomes was confirmed by PCR. The silk glands and silk thread were harvested from these silkworms and their extracts were used to measure the physiological activity of human interferon- β in the form of their antiviral activity. The values are shown in the table after having been corrected for total protein concentrations in the samples.

Promoter	Moth group	Antiviral activity (units/g									
	no	protein)									
	Individual	Posterior	Middle silk	Silk thread							
	no.	silk glands	glands								
Fibroin H	3-1	599723	82591	Not tested							
chain	3-2	656110	41545								
	11-1	502750	19859	,							
	11-2	115560	39130								
Sericin	1-1	Not tested	53884	42187							
	1-2		648953	101713							
	5-1		437291	133288							
	5-2		541106	92749							
Normal s	ilkworms	Not	Not	Not							
		detected	detected	detected							

20

5

10

15

Detection limit: Approx. 1000 units/g protein As a result, since antiviral activity was detected from the posterior and middle silk glands of the silkworms inserted with pigFhIB and antiviral activity was detected from the middle silk glands and silk thread of the silkworms inserted with pigShIB, interferon- β was confirmed to be produced in the silk gland tissue of these silkworms.

Example 11 - Production of Plasmids for Insertion of Feline Granulocyte Colony Stimulating Factor Gene Production of plasmids for insertion of feline granulocyte colony stimulating factor gene was carried out according to the same method as the case of feline interferon- ω gene indicated in Examples 2 through 4.

Feline granulocyte colony stimulating factor gene was obtained in the form of a feline granulocyte colony stimulating factor gene fragment by carrying out PCR using primer 18 (SEQ. ID No. 18) and primer 19 (SEQ. ID No. 19) from cDNA obtained from CRFK cells stimulated for 24 hours with LPS at 10 $\mu g/ml$ according to the report of Yamamoto, et al. (Gene, 274, 263-269, 2001). After treating this fragment with Sall and XbaI, plasmids were constructed that contained a sequence for gene expression in which fibroin H chain gene promoter or sericin gene promoter was coupled to the 5' terminal or poly A signal originating in bovine growth hormone gene was coupled to the 3' terminal (fibroin H chain promoter-feline . granulocyte colony stimulating factor gene-bovine growth hormone gene poly A signal (FGB): SEQ. ID No. 20, sericin gene promoter-feline granulocyte colony stimulating factor gene-bovine growth hormone gene poly A signal (SGB): SEQ. ID No. 21).

The aforementioned FGB and SGB sequences for gene expression were then respectively cleaved from these plasmids by treating with XhoI, and coupled to pigA3GFP that had been subjected to dephosphorylation treatment after being cleaved with XhoI. The plasmid containing the FGB fragment was designated as pigFGB, while the plasmid that contained the SGB fragment was designated as pigSGB. These fragments were purified by centrifuging twice according to the cesium chloride method and then used in a gene insertion experiment.

Example 12 - Production of Feline Granulocyte Colony
Stimulating Factor Gene Recombinant Silkworms

5

10

15

20

25

30

5

10

15

20

25

30

Production of feline granulocyte colony stimulating factor gene recombinant silkworms was carried out according to the same method used to produce feline interferon— ω gene recombinant silkworms indicated in Example 4 by using the gene insertion plasmids produced in Example 11.

Namely, pigFhIB and pigShIB were respectively microinjected into silkworm eggs together with helper plasmid
pHA3PIG, and the resulting adults were crossed followed
by screening of the next generation. When each plasmid
was injected into 600 eggs, silkworms positive for green
fluorescence were obtained in 3 moth groups for silkworms
containing pigFGB and in 7 moth groups for silkworms
containing pigSGB, and insertion of the genes into their
chromosomes was confirmed by PCR. The silk glands and
silk thread were harvested from these silkworms and their
extracts were used to measure the physiological activity
of feline granulocyte colony stimulating factor in the
form of growth promoting activity of NFS-60 cells (ATCC).

Measurement of growth promoting activity was carried out in the manner described below. First, NFS-60 cells were seeded in a 96-well plate in the absence of M-CSF at 2 x 104 cells/well followed 30 minutes later by the addition of 10 μ l of sample. After culturing for an additional 24 hours, cell growth activity was measured using the Cell Counting Kit-8 (Dojindo). The amount of sample that yielded 50% of the maximum growth promoting effect (ED50) was defined as 1 unit/ml, and the physiological activity in the sample was calculated by multiplying by the dilution factor. The values are shown in the table after having been corrected for total protein concentrations in the samples.

Table 5 Growth Promoting Activity in Tissue Extracts of Feline Granulocyte Colony Stimulating Factor Gene Recombinant Silkworms

Promoter	Moth group	Growth promoting activity (units/g									
	no	protein)									
	Individual	Posterior	Middle silk	Silk thread							
	no.	silk glands	glands								
Fibroin H	9-1	36	Not	Not tested							
chain	9-2	412	detected								
	16-1	326	113								
	16-2	4039	226								
			53								
Sericin	3-1	Not tested	4330	590							
	3-2		2277	524							
·	8-1		3966	846							
	8-2		2137	211							
Normal s	ilkworms	Not	Not	Not							
		detected	detected	detected							

Detection limit: Approx. 20 units/g protein

As a result, as growth promoting activity was detected from the posterior and middle silk glands of the silkworms inserted with pigFGB and growth promoting activity was detected from the middle silk glands and silk thread of the silkworms inserted with pigSGB, feline granulocyte colony stimulating factor was confirmed to be produced in the silk gland tissue of these silkworms.

Example 13 - Gene Preparation

A study was conducted on improving production amounts in silk gland tissue and silk thread using feline interferon- ω as a model of a physiologically active protein.

The genes used were acquired by PCR by producing primers for the sequences on both ends using known sequences and using suitable DNA sources for the templates. Restrictase sites were added to the ends of the primers for subsequent gene manipulation.

Fibroin H chain promoter (base numbers 62118-62437 of GenBank registration no. AF226688: to be referred to as the P region) was acquired by PCR using two types of primers consisting of primer 25 (SEQ. ID No. 25) and

20

5

10

primer 26 (SEQ. ID No. 26) and using Bombyx mori genomic DNA for the template.

Fibroin H chain promoter-fibroin H chain gene first exon-first intron-second exon region (base numbers 62118-63513 of GenBank registration no. AF226688: to be referred to as the HP region) was acquired by using two types of primers consisting of primer 25 (SEQ. ID No. 25) and primer 31 (SEQ. ID No. 31) and using Bombyx mori genomic DNA for the template.

Fibroin H chain upstream promoter-fibroin H chain gene first exon-first intron region (base numbers 57444-62927 of GenBank registration no. AF226688: to be referred to as the HUP region) was acquired by PCR using two types of primers consisting of primer 33 (SEQ. ID No. 33) and primer 34 (SEQ. ID No. 34) and using Bombyx mori genomic DNA for the template.

Feline interferon-ω gene (base numbers 9-593 of GenBank registration no. S62636: to be referred to as the IC region) was acquired by PCR using two types of primers consisting of primer 27 (SEQ. ID No. 27) and primer 28 (SEQ. ID No. 28) and using baculovirus rBNV100, which encodes feline interferon-ω gene, for the template. rBNV100 can be produced by, for example, cutting out feline interferon-ω gene from a plasmid extracted from E. coli (pFeIFN1) (Patent Microorganism Depository No. 1633), coupling to a silkworm cloning vector (T. Horiuchi, et al., Agric. Biol. Chem., 51, 1573-1580, 1987), and co-transfecting silkworm established cells with the recombinant plasmid produced and silkworm nuclear polyhedrosis virus DNA.

Fibroin H chain poly A signal region (base numbers 79201-79995 of GenBank registration no. AF226688: to be referred to as the A region) was acquired by PCR using two types of primers consisting of primer 29 (SEQ. ID No. 29) and primer 30 (SEQ. ID No. 30) and using Bombyx mori genomic DNA for the template.

. 5

10

15

20

25

30

Fibroin H chain C terminal region gene-fibroin H chain poly A signal region (base numbers 79099-79995 of GenBank registration no. AF226688: to be referred to as the HA region) was acquired by PCR using two types of primers consisting of primer 32 (SEQ. ID No. 32) and primer 30 (SEQ. ID No. 30) and using Bombyx mori genomic DNA for the template.

 β -galactosidase (β -gal) gene was acquired by PCR using two types of primers consisting of primer 37 (SEQ. ID No. 37) and primer 38 (SEQ. ID No. 38) and using p β gal-Basic vector (Clontech) for the template.

PCR was carried out in accordance with the accompanying protocol using KODplus (Toyobo). Namely, after adding 100 ng of each template in the case of Bombyx mori genomic DNA or 10 ng in the case of Bombyx mori posterior silk gland cDNA and p β gal-Basic vector, 50 pmol of each primer and 10 μ l of the 10xPCR buffer provided, each reagent was added to a concentration of 1 mM MgCl₂, 0.2 mM dNTPs and 2 units of KODplus followed by bringing to a final volume of 100 μ l. The PCR components were then reacted for 30 cycles using a Perkin-Elmer DNA thermal cycler under DNA denaturation conditions of 94°C for 15 seconds, primer annealing conditions of 55°C for 30 seconds, and elongation conditions of 68°C for 60 to 300 seconds.

These reaction solutions were electrophoresed with 1 to 1.5% agarose gel, and a DNA fragment of roughly 0.3 kbp in the P region, roughly 1.4 kbp in the HP region, roughly 5.5 kbp in the HUP region, roughly 580 bp in the IC region, roughly 0.8 bp in the A region, roughly 0.9 bp in the HA region and roughly 3.2 kbp in the β -gal gene were extracted and prepared in accordance with ordinary methods. After phosphorylating these DNA fragments with polynucleotide kinase (Takara Shuzo), they were ligated to pUC19 vector subjected to dephosphorylation treatment

5

10

15

20

25

30

after being cleaved with HincII by reacting overnight at 16°C using DNA Ligation Kit Ver. 2 (Takara Shuzo). These were then used to transform *E. coli* in accordance with ordinary methods and the resulting transformants were confirmed to be inserted with PCR fragments by performing PCR on the resulting colonies under the same conditions as previously described to prepare plasmids in which the PCR fragments were inserted according to ordinary methods. These plasmids were sequenced to confirm that the resulting fragments consisted of the base sequences of each gene.

Example 14 - Production of Plasmids for Expression of β-Galactosidase

The plasmid retaining β -gal gene prepared in Example 13 was cleaved with SalI and HindIII followed by insertion therein of a roughly 0.3 kbp fragment (P region) cleaved by SalI and HindIII from a plasmid retaining fibroin H chain promoter. Moreover, this was then cleaved with BamHI followed by insertion therein of a roughly 0.8 kbp region (A region) cleaved with BamHI from a plasmid having a fibroin H chain poly A signal region, and purifying the resulting plasmid retaining the β -gal gene using the Qiagen Plasmid Maxi Kit in accordance with the protocol provided. The resulting plasmid was named pPgalA, and it was confirmed to be the target plasmid by PCR and sequencing.

Similarly, the plasmid retaining the β -gal gene prepared in Example 13 was cleaved with SalI and HindIII followed by insertion therein of a roughly 1.4 kbp fragment (HP region) cleaved with SalI and HindIII from a plasmid retaining the fibroin H chain promoter-fibroin H chain gene first exon-first intron-second exon region. Moreover, this was then cleaved with BamHI followed by insertion therein of a roughly 0.9 kbp fragment (HA region) cleaved with BamHI from a plasmid retaining a fibroin H chain C terminal region-fibroin H chain poly A

5

10

15

20

25

30

signal region, and purifying the resulting plasmid retaining the $\beta\text{-gal}$ gene using the Qiagen Plasmid Maxi Kit in accordance with the protocol provided. The resulting plasmid was named pHPgalHA, and it was confirmed to be the target plasmid by PCR and sequencing.

Example 15 - Production of Plasmids for Gene Insertion

pigA3GFP (Nature Biotechnology 18, 81-84, 2000) was used for the plasmid for gene insertion. Namely, vector pigA3GFP is a vector in which after removing a region encoding transposase from plasmid p3E1.2 disclosed in US Patent No. 6218185, an A3 promoter (base numbers 1764-2595 of GenBank registration no. U49854), GFP originating in pEGFP-N1 vector (Clontech) and poly A addition sequence originating in SV40 (base numbers 659-2578 of GenBank registration no. U55762) are inserted into that portion. The XhoI site located upstream from the A3 promoter was blunt ended followed by insertion of an expression cassette of feline interferon- ω gene. constitution of the gene expression cassette used in the present example consisted of fibroin H chain promoterfeline interferon- ω -fibroin H chain C terminal regionfibroin H chain poly A signal region (HP-IC-HA), or fibroin H chain upstream promoter-fibroin H chain gene first exon-first intron-second exon region-feline interferon-ω-fibroin H chain C terminal region-fibroin H chain poly A signal region (HUP-IC-HA), or fibroin H chain promoter-fibroin H chain gene first exon-first intron-second exon region-feline interferon-ω-fibroin H chain poly A signal region (HP-IC-A).

The following indicates the specific method employed.

The P-IC-A construct was produced according to the following procedure. The plasmid retaining feline interferon- ω (IC region) prepared in Example 13 was

5

10

15

20

25

30

cleaved with SalI and HindIII followed by insertion therein of a roughly 0.3 kbp fragment (P region) cleaved with SalI and HindIII from a plasmid retaining fibroin H chain promoter. Moreover, this was cleaved with BamHI followed by insertion therein of a roughly 0.8 kbp fragment (region A) cleaved with BamHI from a plasmid retaining fibroin H chain poly A signal region. This plasmid retaining P, IC and A was cleaved with AscI and the cleaved roughly 1.7 kbp fragment was blunt ended with T4 DNA Polymerase (Takara Shuzo) and coupled to blunt ended and dephosphorylated pigA3GFP XhoI site to produce a construct for gene insertion containing the P-IC-A gene cassette. The procedure is shown in Figs. 9 and 10.

. The HP-IC-HA construct was produced in the following The plasmid retaining feline interferon- ω (IC region) prepared in Example 13 was cleaved with SalI and HindIII followed by insertion therein of a roughly 1.4 kbp fragment (HP region) cleaved with SalI and HindIII from a plasmid retaining a fibroin H chain promoterfibroin H chain gene first exon-first intron-second exon region. Moreover, this was cleaved with BamHI followed by insertion therein of a roughly 0.9 kbp fragment (region HA) cleaved with BamHI from a plasmid retaining fibroin H chain C terminal region-fibroin H chain poly A signal region. This plasmid retaining HP, IC and HA was cleaved with AscI and the cleaved roughly 2.9 kbp fragment was blunt ended with T4 DNA Polymerase (Takara Shuzo) and coupled to blunt ended and dephosphorylated pigA3GFP XhoI site to produce a construct for gene insertion containing the HP-IC-HA gene cassette. The procedure is shown in Figs. 11 and 12.

The HUP-IC-HA construct was produced according to the following procedure. A roughly 2.1 kbp fibroin H chain first intron-second exon region-feline interferon- ω -fibroin H chain C terminal region-fibroin H chain poly A signal region was acquired by PCR using two types of

10

15

20

25

30

primers consisting of primer 35 (SEQ. ID No. 35) and primer 36 (SEQ. ID No. 36) and using 1 ng of HP-IC-HA construct for the template. This was then cleaved with XhoI and SphI followed by insertion therein of a roughly 5.5 kbp fragment (HUP region) cleaved with XhoI and SphI from a plasmid retaining fibroin H chain upstream promoter-fibroin H chain gene first exon-first intron. This plasmid retaining HUP, IC and HA was cleaved with AscI and the cleaved roughly 7.6 kbp fragment was blunt ended with T4 DNA Polymerase (Takara Shuzo) and coupled to blunt ended and dephosphorylated pigA3GFP XhoI site to produce a construct for gene insertion containing the HUP-IC-HA gene cassette. The procedure is shown in Figs. 13 and 14.

The HP-IC-A construct was produced according to the procedure described below. The plasmid retaining feline interferon-ω (IC region) prepared in Example 13 was cleaved with SalI and HindIII followed by insertion therein of a roughly 1.4 kbp fragment (HP region) cleaved with SalI and HindIII from a plasmid retaining fibroin H chain promoter-fibroin H chain first exon-first intronsecond exon region. Moreover, this was cleaved with BamHI followed by insertion therein of a roughly 0.8 kbp fragment (region A) cleaved with BamHI from a plasmid retaining fibroin H chain poly A signal region. plasmid retaining HP, IC and A was cleaved with AscI and the cleaved roughly 2.8 kbp fragment was blunt ended with T4 DNA Polymerase (Takara Shuzo) and coupled to blunt ended and dephosphorylated pigA3GFP XhoI site to produce a construct for gene insertion containing the HP-IC-A gene cassette. The procedure is shown in Figs. 15 and 16.

The P-IC-A gene insertion construct, HP-IC-HA gene insertion construct, HUP-IC-HA gene insertion construct and HP-IC-A gene insertion construct were purified using the Qiagen Plasmid Maxi Kit in accordance with the protocol provided.

5

10

15

20

25

30

Example 16 - Expression of β -Galactosidase in Silkworm Silk Gland

Gold particles having a diameter of 1.6 µm were washed and sterilized with 100% ethanol and then suspended in sterilized distilled water (60 mg/ml). Incorporation of β -gal gene expression cassettes into silkworm silk glands was carried out using a gene gun. Namely, 50 μ l (0.3 mg) of gold particles, 10 μ g of expression plasmid pPgalA or pHPgalHA obtained in Example 14, 50 μ l of 2.5 M calcium chloride and 20 μ l of 0.1 M spermidine were successively mixed and after allowing to stand for 30 minutes at room temperature, the mixture was centrifuged to recover the gold particles coated with pHgalC. After washing the resulting metal particles twice with 70% ethanol, they were dispersed in 50 µl of 100% ethanol. 10 μl of the suspension of gold particles The Model PDSwere placed on a microcarrier and dried. 1000/He (Bio-Rad) was used for the gene gun. posterior silk glands excised from fifth instar third day silkworm larva were gently washed twice with PBS, placed on a 1% agar plate and sprayed with gold particles coated with DNA at a pressure of 1,100 psi. Following insertion of DNA, the silk glands were transferred to 20 ml of Grace's insect medium and cultured for 2 days at 25°C. After culturing, the culture supernatant and silk gland cells were recovered and confirmed for the expression of β -gal.

Expression was confirmed by Western analysis. The silk gland cells were homogenized in PBS to extract the cell contents. The culture supernatant and cell extract were both adjusted to a total protein concentration of 1.0 mg/ml, and these were then used as samples for SDS-PAGE. After blotting onto a membrane, β -gal protein was detected using the ECL PlusTM Western Blotting Kit

5

10

15

20

25

(Amersham-Pharmacia) in accordance with the protocol provided. Namely, the blotted membrane was first blocked overnight at 4°C in blocking solution (5% skim milk, 0.1% Tween20/PBS). The membrane was then washed twice with TPBS (0.1% Tween 20/PBS) and treated for 1 hour at room temperature with anti- β -gal protein antibody (Sigma) diluted 1000-fold with TPBS. The membrane was washed twice with TPBS and additionally washed three times with TPBS for 5 minutes each. After diluting 10000-fold with TPBS, the membrane was treated for 1 hour at room temperature with HRP-labeled anti-rabbit IgG antibody. After washing the membrane twice with TPBS and then three times with TPBS for 5 minutes each, the detection reagents of the ECL PlusTM Western Blotting Detection System (Amersham-Pharmacia) were added (Solution A + Solution B). Luminescence was then exposed onto HyperfilmTMECLTM and developed.

Since β -gal protein was only detected in the silk gland cells and culture supernatant containing pHPgalHA, it was clearly determined that a region other than fibroin H chain promoter, namely fibroin H chain gene first exon-first intron-second exon region, plays an important role in protein synthesis or gene expression within the cells. In addition, secretion outside the cells was also confirmed. Those results are shown in Fig. 17.

Example 17 - Production of Recombinant Gene Silkworms

Each of the gene insertion plasmids described in Example 15 and DNA that produces piggyBac transposase protein (pHA3PIG) were adjusted to a concentration of 200 μ g/ml each in 0.5 mM phosphate buffer (pH 7.0) and 5 mM KCl, after which 3 to 20 nl were micro-injected into silkworm eggs within 4 hours after being laid.

The larva that hatched from those silkworm eggs were raised, and the resulting adults (G0) were crossed within

5

10

15

20

25

30

the same group. By observing the resulting first generation (G1) individuals for fluorescence of jellyfish green fluorescence protein, those silkworms that contained the jellyfish green fluorescence protein gene in their chromosomes were screened. As a result, gene recombinant silkworms were obtained that emitted fluorescent light due to the action of the jellyfish green fluorescence protein.

Example 18 - Expression Analysis of Recombinant
Protein in Silk Gland Tissue by Western Analysis

The expression of feline interferon- ω in tissue was investigated by Western analysis after recovering the posterior silk gland tissue from non-transformed silkworms and transformed silkworms (HP-IC-A transformed silkworms, HP-IC-HA transformed silkworms and HUP-IC-HA transformed silkworms). The silkworm posterior silk glands were homogenized in 100 mM sodium phosphate buffer (pH 7.0), and the supernatant was recovered following centrifugation for use as samples. Feline interferon was then detected using the ECL PlusTM Western Blotting Kit (Amersham-Pharmacia) in accordance with the protocol provided. Namely, the blotted membrane was blocked overnight at 4°C in blocking solution (5% skim milk, 0.1% Tween20/PBS). The membrane was then washed twice with TPBS (0.1% Tween 20/PBS) and treated for 1 hour at room temperature with anti-feline interferon antibody diluted 1000-fold with TPBS. The membrane was washed twice with TBPS and additionally washed three times with TPBS for 5 minutes each. After diluting 10000-fold with TPBS, the membrane was treated for 1 hour at room temperature with HRP-labeled anti-rabbit IgG antibody. After washing the membrane twice with TPBS and then three times with TPBS for 5 minutes each, the detection reagents of the ECL PlusTM Western Blotting Detection System (Amersham-Pharmacia) were added (Solution A + Solution B). Luminescence was then exposed onto HyperfilmTMECLTM and developed. As a result, in contrast to signals not being

5

10

15

20

25

detected from posterior silk gland tissue of the nontransformed silkworms and P-IC-A construct transformed silkworms, signals were detected from the posterior silk gland tissue of transformed silkworms containing the HP-IC-A construct, HP-IC-HA construct and HUP-IC-HA construct. Based on the results of this experiment, a region other than the fibroin H chain promoter, namely the fibroin H chain gene first exon-first intron-second exon region, was reconfirmed to play an important role in drastically improving protein synthesis or gene expression within silkworm posterior silk gland cells. These results are shown in Fig. 18. The accumulated amount of feline interferon in posterior silk gland tissue in the transformed silkworms containing the HUP-IC-HA gene cassette that contains the 5.5 kbp fibroin H chain 5' terminal region, feline interferon gene and fibroin H chain 3' terminal was higher than the accumulated amount of feline interferon in posterior silk gland tissue in transformed silkworms containing the HP-IC-HA gene cassette that contains the fibroin H chain 5' terminal promoter region, feline interferon gene and fibroin H chain 3' terminal. A gene region that improved the amount of protein produced is thought to be present in a region upstream from the H chain 5' terminal.

Example 19 - Measurement of Recombinant Protein in Silk Thread by Western Analysis

Next, the secretion of exogenous protein, namely feline interferon- ω , in silk thread was investigated.

10 mg each of the cocoons from non-transformed silkworms and transformed silkworms (transformed silkworms containing the HP-IC-A gene, transformed silkworms containing the HP-IC-HA gene, and transformed silkworms containing the HUP-IC-HA gene) were weighed out, and after adding 4 ml of 60% LiSCN and stirring, the cocoons were dissolved by allowing to mix overnight at room temperature. The dissolved cocoons were then diluted 10-fold with 8 M urea, 2% SDS and 5% 2-

5

10

15

20

25

30

mercaptoethanol to prepare samples. The levels of feline interferon in the samples were then detected using the ECL PlusTM Western Blotting Kit (Amersham-Pharmacia) in accordance with the protocol provided. Those results were then measured for signal intensity using a Molecular Imager (Bio-Rad) and the protein contents were measured by comparing with the signal intensities of known concentrations of feline interferon.

As a result, in contrast to signals not being detected from the cocoons of the non-transformed silkworms and transformed silkworms containing HP-IC-A gene, signals were detected from the cocoons of transformed silkworms containing HP-IC-HA gene and transformed silkworms containing HUP-IC-HA gene, thereby confirming that feline interferon protein is secreted into silk thread. In addition, the content was about 0.8 to 2.0% in HP-IC-HA transformed silkworms, and about 1.8 to 5.4% in HUP-IC-HA transformed silkworms. This is equivalent to 0.4 to 2 mg in terms of the weight per silkworm.

On the basis of the results of this experiment, the 3' terminal portion of fibroin H chain gene was clearly demonstrated to play an important role in the secretion of protein synthesized in posterior silk gland cells into silk thread. These results are shown in Fig. 19. The amount of feline interferon produced in transformed silkworms containing the HUP-IC-HA gene cassette that contains a 5.5 kbp fibroin H chain 5' terminal promoter region, feline interferon gene and fibroin H chain 3' terminal was higher than the amount of feline interferon produced in transformed silkworms containing the HP-IC-HA gene cassette that contains fibroin H chain 5' terminal promoter region, feline interferon gene and fibroin H chain 3' terminal. A gene region that improves the amount of protein produced is considered to be present in a region upstream from the H chain 5' terminal.

5

10

15

20

25

30

Example 20 - Measurement of Recombinant Protein in Silk Thread by ELISA

Quantitative determination of feline interferon- ω in silk thread was carried out.

10 µg each of the cocoons from non-transformed silkworms and transformed silkworms (transformed silkworms containing the HP-IC-A gene, transformed silkworms containing the HP-IC-HA gene, and transformed silkworms containing the HUP-IC-HA gene) were weighed out, and after adding 4 ml of 60% LiSCN and stirring, the cocoons were dissolved by allowing them to mix overnight at room temperature. The dissolved cocoons were diluted 8-fold or 16-fold with PBS and applied to a microtiter plate. Known concentrations of feline interferon serially diluted with PBS were used for the standards.

As a result, feline interferon- ω was not detected in silk thread in transformed silkworms containing HP-IC-A gene, but was detected at about 1.1 to 2.2% in transformed silkworms containing HP-IC-HA gene, and at about 1.0 to 4.9% in transformed silkworms containing HUP-IC-HA gene.

INDUSTRIAL APPLICABILITY

A cytokine could be recovered in large volume while retaining its physiological activity from the silk glands or silk thread of gene recombinant silkworms obtained by producing a plasmid vector, in which a cytokine gene is coupled to a promoter that functions in silkworm silk glands, and then inserting those genes into silkworm chromosomes. In addition, the resulting cytokine extract has a low level of contaminating proteins, and can be purified easily as compared with methods of the prior art.

A large amount of exogenous protein could be produced within silk gland cells, outside silk gland cells and in silk thread by inserting an expression gene

. 5

10

15

20

25

30

cassette, in which the DNA sequence of the 5' terminal portion and the DNA sequence of the 3' terminal portion of fibroin H chain gene were fused to an exogenous protein gene, into silk gland cells and so forth. The use of this novel technique led to the establishment of a technology for producing easily purified exogenous protein by producing exogenous protein using silk glands without the use of a recombinant baculovirus.

SEQUENCE LISTING

```
<110>Toray Industries, Inc.
<110>National Institute of Agrobiological Science
<120>Process for production of physiologically active
     proteins using recombinant silkworm
<130>
<160>38
<210>1
<211>1910
<212>DNA
<213>Artificial sequence
<220>
<221>CDS
<222>(1071)...(1652)
<221>sig peptide
<222>(1071)...(1139)
<221>mat_peptide
<222>(1140)...(1652)
<400>1
ctcgagggtc agaaaccttg ttaaccaata gagccaaata tagttaacac aatagaaatt
                                                                  60
tatccaaata ttattcgtgt attgtttata gcctttgtca agtcttttac aaggcaagat
                                                                 120
aataagtaat atteegtgat tggacgtaac attteeegga agateettag eegataagte
                                                                 180
gaagagccgc atgtggctag agagacgcgg gtttccgacc actggcttag gcgcttattc
                                                                 240
egecataata gatgtaegtg tteacaatta geaceegaaa ttegtaatag etaegagaag
                                                                 300
tatogaatat caaaaatota tatattaata ogtgaagoaa aaactttgta tooctttta
                                                                 360
cgaaaattgc gaggacggag gagtatgaaa tttcccacac ttatagagaa tacagagaag
                                                                 420
aagtgcacaa tgctaatatt tttttaaaat aatgcataaa agatacttta aatcaataaa
                                                                 480
                                                                 540
gaaaacagca cacacactac ataccatgta tttgacgcac acacgcatgt atactattta
ttgtcaaact tttgttcttg acgtctgtgt tcaaactgag aatagattaa atattgtttg
                                                                 600
tetttattaa tatttttaa tagtgtagte ttggcgaaat ttgtgattat agaagtataa
                                                                 660
aatacaatca taatagtgta caaacttaca attcccaatt aattatagtc gaatttcgac
                                                                 720
```

780

840

tactgcggga cctctagtat taataattct ctttaaaaaa aaacagagca tcaaatactg

tcacaaatgt caagcgggtc tcaacgagcc atgaataaat tagaaatcaa ttaataacat

aaa	atag	gca :	aaca	aaat	aa a	acca	ttta	c at	agag	aacg	ttt	gttga	aac :	aaaa:	acaata	900
act	tgta	tac :	attg	tttg	ca c	aaat	gttt	g aa	ccga	aaat	tta	ttac	tet (ctac	gtaagc	960
ttg	atca	aac	ttcg	tttt	eg t	ataa	aacg	c gt	tgga	ccaa	cca	cttt	gge a	atag	tegtet	1020
tat	cate	ggg '	tete	taag	ga t	caag	cgate	c ca	aaga	gege	caa	cgtc	gac :	atg (geg	1076
							•							Met 2		
														1		
ctg	ccc	tct	tcc	ttc	ttg	gtg	gcc	ctg	gtg	gcg	ctg	ggc	tge	aac	tcc	1124
			Ser													
		5					10					15		,		
gtc	tgc	gtg	ctg	ggc	tgt	gac	ctg	cct	cag	acc	cac	ggc	ctg	ctg	aac	1172
Val	Cys	Val	Leu	Gly	Cys	Asp	Leu	Pro	Gln	Thr	His	Gly	Leu	Leu	Asn	
	20					25					30		,			
agg	agg	gcc	ttg	acg	ctc	ctg	gga	caa	atg	agg	aga	ctc	cct	gcc	agc .	1220
Arg	Arg	Ala	Leu	Thr	Leu	Leu	Giy	Gln	Met	Arg	Arg	Leu	Pro	Ala	Ser	
35					40					45					50	
tcc	tgt	cag	aag	gac	aga	aat	gac	ttc	gaa	ttc	ccc	cag	gac	gtg	ttc	1268
Ser	Cys	Gln	Lys	Asp	Arg	Asn	Asp	Phe	Ala	Phe	Pro	Gln	Asp	Val	Phe	
				55					. 60					65		
ggt	gga	gac	cag	tec	cac	aag	gcc	caa	gcc	ctc	tcg	gtg	gtg	cac	gtg	1316
Gly	Gly	Asp	Gln	Ser	His	Lys	Ala	Gln	Ala	Leu	Ser	Val	Val	His	Val	
			70					75					80			
acg	aac	cag	aag	atc	ttc	cac	ttc	ttc	tgc	aca	gag	gcg	tcc	tcg	tct	1364
Thr	Asn	Gln	Lys	Ile	Phe	His	Phe	Phe	Cys	Thr	Glu	Ala	Ser	Ser	Ser	
•		85	•		. ,		90					95				
gct	gct	tgg	aac	acc	acc	ctc	ctg	gag	gaa	ttt	tgc	acg	gga	ctt	gat	1412
Ala	Ala	Trp	Asn	Thr	Thr	Leu	Leu	Glu	Glu	Phe	Cys	Thr	Gly	Leu	Asp	
	100					105					110					
cgg	cag	ctg	acc	cgc	ctg	gaa	gcc	tgt	gtc	ctg	cag	gag	gtg	gag	gag	1460
Arg	Gln	Leu	Thr	Arg	Leu	Glu	Ala	Cys	Val	Leu	Gln	Glu	Val	Glu	Glu	
115					120					125	•				130	
gga	gag	gct	ccc	ctg	acg	aac	gag	gac	att	cat	ccc	gag	gac	tac	atc	1508
Cly	Glu	Ala	Pro	Leu	Thr	Asn	Glu	Asp	Ile	His	Pro	Glu	Asp	Ser	Ile	
				125					1 40							

ctg agg aac tac ttc caa aga ctc tcc ctc tac ctg caa gag aag aaa	1556
Leu Arg Asn Tyr Phe Gln Arg Leu Ser Leu Tyr Leu Gln Glu Lys Lys	
150 155 160	
tac age cet tgt gee tgg gag atc gtc aga gca gaa atc atg aga tcc	1604
Tyr Ser Pro Cys Ala Trp Glu Ile Val Arg Ala Glu Ile Met Arg Ser	
165 170 175	
ttg tat tat tca tca aca gcc ttg cag aaa aga tta agg agc gag aaa	1652
Leu Tyr Tyr Ser Ser Thr Ala Leu Gln Lys Arg Leu Arg Ser Glu Lys	
180 185 190	
tga tctagaccgc tgatcagcct cgactgtgcc ttctagttgc cagccatctg	1705
ttgtttgccc ctcccccgtg ccttccttga ccctggaagg tgccactccc actgtccttt	1765
cctaataaaa tgaggaaatt gcatcgcatt gtctgagtag gtgtcattct attctggggg	1825
gtggggtggg gcaggacagc aagggggagg attgggaaga caatagcagg catgctgggg	1885
atgcggtggg ctctatggcc tcgag	1910
<210>2	
<211>1172	
<212>DNA	
<213>Artificial sequence	
<220>	
<221>CDS	
<222>(333)(914)	
<221>sig_peptide	
<222>(333)(401)	
<221>mat_peptide	
<222>(402)(914)	
<400>2	
ctcgagggga gaaagcatga agtaagttct ttaaatatta caaaaaaatt gaacgatatt	60
ataaaattot ttaaaatatt aaaagtaaga acaataagat caattaaatc ataattaatc	120
acattgttca tgatcacaat ttaatttact tcatacgttg tattgttatg ttaaataaaa	180
agattaattt ctatgtaatt gtatctgtac aatacaatgt gtagatgttt attctatcga	240
aagtaaatac gtcaaaactc gaaaattttc agtataaaaa ggttcaactt tttcaaatca	300
geatcagtte ggtteeaact etcaaggteg ac atg geg etg eee tet tee tte	353

									Met	Ala	Leu	Pro	Ser	Ser	Phe		
									1				5				
ttg	gtg	gcc	ctg	gtg	gcg	ctg	ggc	tgc	aac	tcc	gtc	tgc	gtg	ctg	ggc	40	1
Leu	Val	Ala	Leu	Val	Ala	Leu	Gly	Cys	Asn	Ser	Val	Cys	Val	Leu	Gly		
		10			•		. 15					20					
tgt	gac	ctg	cct	cag	acc	cac	ggc	ctg	ctg	aac	agg	agg	gcc	ttg	acg	44	9
Cys	Asp	Leu	Pro	Gln	Thr	His	Gly	Leu	Leu	Asn	Arg	Arg	Ala	Leu	Thr		
	25					30					35						
ctc	atg	g ga	caa	atg	agg	aga	ctc	cct	gcc	agc	toc	tgt	cag	aag	gac	49	7 .
Leu	Leu	Gly	Gln	Met	Arg	Arg	Leu	Pro	Ala	Ser	Ser	Суз	Gln	Lys	Asp		
40					45					50					55		
aga	aat	gac	ttc	gcc	ttc	ccc	cag	gac	gtg	ttc	ggt	gga	gac	cag	tcc	54	5
Arg	Asn	Asp	Phe	Ala	Phe	Pro	Gln	Asp	Val	Phe	Gly	Gly	Asp	Gln	Ser		
				60					65					70			
cac	aag	gcc	caa	gcc	ctc	tcg	gtg	gtg	cac	gtg	acg	aac	cag	aag	atc	59	3
His	Lys	Ala	Gln	Ala	Leu	Ser	Val	Val	His	Val	Thr	Asn	Gln	Lys	Ile		
			75					80					85				
ttc	cac	ttc	ttc	tgc	aca	gag	gcg	tcc	tcg	tct	gct	gct	tgg	aac	acc	64	1
Phe	His	Phe	Phe	Cys	Thr	Glu	Ala	Ser	Ser	Ser	Ala	Ala	Trp	Asn	Thr		
		90					95					100					
acc	ctc	ctg	gag	gaa	ttt	tgc	acg	gga	ctt	gat	cgg	cag	ctg	acc	cgc	68	9
Thr	Leu	Leu	Glu	Glu	Phe	Cys	Thr	Gly	Leu	Asp	Arg	Gln	Leu	Thr	Arg		
	105					110					115					÷	
_	gaa	-	_	-	_	_										73	7
Leu	Glu	Ala	Cys	Val	Leu	Gln	Glu	Val	Glu		Gly	Glu	Ala	Pro	Leu		•
120					125					130					135		
acg	aac	gag	gac	att	cat	ccc	gag	gac	tee	atc	ctg	agg	aac	tac	ttc	78	5
Thr	Asn	Glu	Asp	Ile	His	Pro	Glu	Asp	Ser	Ile	Leu	Arg	Asn	Tyr	Phe		
				140					145					150			
caa	aga	ctc	tcc	ctc	tac	ctg	caa	gag	aag	aaa	tac	agc	cct	tgt	gcc	83	3
Gln	Arg	Leu	Ser	Leu	Tyr	Leu	Gln	Glu	Lys	Lys	Tyr	Ser	Pro	Cys	Ala		
			155					160					165				
tgg	gag	atc	gtc	aga	gca	gaa	atc	atg	aga	tcc	ttg	tat	tat	tca	tca	88	1.

Trp Glu Ile Val Arg Ala Glu Ile Met Arg Ser Leu Tyr Tyr Ser Ser	•
170 175 180	
aca gcc ttg cag aaa aga tta agg agc gag aaa tga tctagaccgc	927
Thr Ala Leu Gln Lys Arg Leu Arg Ser Glu Lys	
185 190	
tgatcagcct cgactgtgcc ttctagttgc cagccatctg ttgtttgccc ctccccgtg	987
ccttccttga ccctggaagg tgccactccc actgtccttt cctaataaaa tgaggaaatt	1047
gcatcgcatt gtctgagtag gtgtcattct attctggggg gtggggtggg	1107
aagggggagg attgggaaga caatagcagg catgctgggg atgcggtggg ctctatggcc	1167
togag	1172
<210>3	
<211>31	
<212>DNA	
<213>Artificial sequence	
<220>	
<223>Synthesized oligonucleotide	
<400>3	
acgegtegae atgggegetg ecetetteet t	31
<210>4	
<211>30	
<212>DNA	
<213>Artificial sequence	•
<220>	
<223>Synthesized oligonucleotide	
<400>4	
ctagtctaga tcatttctcg ctccttaatc	30
<210>5	
<211>29	
<212>DNA	·
<223>Artificial sequence	•
<220>	
<223>Synthesized oligonucleotide	
<400>5	

coggaattog gtcagaaacc ttgttaacc		29
<210>6		
<211>30		
<212>DNA		
<213>Artificial sequence		
<220>		
<223>Synthesized oligonucleotide		
<400>6		•
acgcgtcgac gttggcggtc tttggatcgc		30
<210>7		
<211>29		
<212>DNA		
<213>Artificial sequence		
<220>		
<223>Synthesized oligonucleotide		٠
<400>7		
ccggaattcg ggagaaagca tgaagtaag		29
<210>8		
<211>30		
<212>DNA		
<213>Artificial sequence		
<220>		
<223>Synthesized oligonucleotide		
<400>8		
acgcgtcgac cttgagagtt ggaaccgaac	•	30
<210>9	•	
<211>30		
<212>DNA		
<213>Artificial sequence		
<220>	•	
<223>Synthesized oligonucleotide		
<400>9		
ctagtotaga conctgatoa gootogacto		30

<210>10	
<211>30	
<212>DNA	
<213>Artificial sequence	
<220>	
<223>Synthesized oligonucleotide	
<400>10	
egeggateeg ceatagagee cacegeatee	30
<210>11	
<211>34	
<212>DNA	
<213>Artificial sequence	
<220>	
<223>Synthesized oligonucleotide	
<400>11	
gacctcgagg gtcagaaacc ttgttaacca atag	34
<210>12	
<211>30	
<212>DNA	
<213>Artificial sequence	
<220>	
<223>Synthesized oligonucleotide	
<400>12	
gacctegagg ceatagagec caccgcatec	30
<210>13	
<211>29	
<212>DNA	
<213>Artificial sequence	
<220>	
<223>Synthesized oligonucleotide	
<400>13	
gacctcgagg ggagaaagca tgaagtaag	29
<210>14	

<211>31		
<212>DNA		
<213>Artificial sequence		
<220>		
<223>Synthesized oligonucleotide		
<400>14		
acgcgtcgac atgaccaaca agtgtctcct c	3	31
<210>15		
<211>30		
<212>DNA		
<213>Artificial sequence		
<220>		
<223>Synthesized oligonucleotide		
<400>15		
ctagtctaga tcagtttcgg aggtaacctg	3	30
<210>16		
<211>1151		
<212>DNA		
<213>Artificial sequence		
<220>		
<221>CDS		
<222>(333)(893)		
<221>sig_peptide		
<222>(333)(395)		
<221>mat_peptide		
<222>(396)(893)		
<400>16		
ctcgagggga gaaagcatga agtaagttot ttaaatatta caaaaaaatt gaa	cgatatt	60
ataaaattot ttaaaatatt aaaagtaaga acaataagat caattaaato ata	attaatc 1	20
acattgttca tgatcacaat ttaatttact tcatacgttg tattgttatg tta	aataaaa 19	ВС
agattaattt ctatgtaatt gtatctgtac aatacaatgt gtagatgttt att	ctatoga 2	4 C
aagtaaatac gtcaaaactc gaaaattttc agtataaaaa ggttcaactt ttt	caaatca 30	00

gcatcagttc ggttccaact ctcaaggtcg ac

atg	acc	aac	aag	tgt	ctc	ctc	caa	att	gct	ctc	ctg	ttg	tgc	ttc	tcc	380
Met	Thr	Asn	Lys	Cys	Leu	Leu	Gln	Ile	Ala	Leu	Leu	Leu	Cys	Phe	Ser	
. 1				5			•		10					15		
act	aca	gct	ctt	tcc	atg	agc	tac	aac	ttg	ctt	gga	ttc	cta	caa	aga	428
Thr	Thr	Ala	Leu	Ser	Met	Ser	Tyr	Asn	Leu	Leu	Gly	Phe	Leu	Gln	Arg	
			20					25					30			
agc	agc	aat	ttt	cag	tgt	cag	aag	ctc	ctg	tgg	caa	ttg	aat	ggg	agg	476
Ser	Ser	Asn	Phe	Gln	Cys	Gln	Lys	Leu	Leu	Trp	Glņ	Leu	Asn	Gly,	Arg	
		35					40					45				
ctt	gaa	tac	tgc	ctc	aag	gac	agg	atg	aac	ttt	gac	atc	cct	gag	gag	524
Leu	Glu	Tyr	Суз	Leu	Lys	Asp	Arg	Met	Asn	Phe	Asp	Ile	Pro	Glu	Glu	
	50					55					60					
att	aag	cag	ctg	cag	cag	ttc	cag	aag	gag	gac	gcc	gça	ttg	acc	atc	572
Ile	Lys	Gln	Leu	Gln	Gln	Phe	Gln	Lys	Glu	Asp	Ala	Ala	Leu	Thr	Ile	
65					70					75					80	•
tat	gag	atg	ctc	cag	aac	atc	ttt	gct	att	ttc	aga	caa	gat	tca	tct	620
Tyr	Glu	Met	Leu	Gln	Asn	Ile	Phe	Ala	Ile	Phe	Arg	Gln	Asp	Ser	Ser	
.*				85					90					95		
agc	act	ggc	tgg	aat	gag	act	att	gtt	gag	aac	ctc	ctg	gct	aat	gtc	668
Ser	Thr	Gly	Trp	Asn	Glu	Thr	Ile	Val	Glu	Asn	Leu	Leu	Ala	Asn	Val	
			100					105			٠.		110			
tat	cat	cag	ata	aac	cat	ctg	aag	aca	gtc	ctg	gaa	gaa	aaa	ctg	gag	716
Tyr	His	Gln	Ile	Asn	His	Leu	Lys	Thr	Val	Leu	Glu		Lys	Leu	Glu	
		115					120					125				
aaa	gaa	gat	ttc	acc	agg	gga	aaa	ctc	atg	agc	agt	ctg	cac	ctg	aaa	764
Lys		Asp	Phe	Thr	Arg		Lys	Leu	Met	Ser		Leu	His	Leu	Lys	
	130					135					140					
aga	tat	tat	ggg	agg	att	ctg	cat	tac	ctg	aag	gcc	aag	gag	tac	agt	812
Arg	Tyr	Tyr	Gly	Arg	Ile	Leu	His	Tyr	Leu	Lys	Ala	Lys	Glu	Tyr	Ser	
145					150					155					160	
cac	tgt	gcc	tgg	acc	ata	gtc	aga	gtg	gaa	atc	cta	agg	aac	ttt	tac	860
His	Суз	Ala	Trp	Thr	Ile	Val	Arg	Val		Ile	Leu	Arg	Asn		Tyr	
				165					170					175		

tto att aac aga ott aca ggt tac otc oga aac tga totagacogo	906
Phe Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn	
180 185	
tgatcagcct cgactgtgcc ttctagttgc cagccatctg ttgtttgccc ctcccccgtg	960
ccttccttga ccctggaagg tgccactccc actgtccttt cctaataaaa tgaggaaatt	1026
gcatcgcatt gtctgagtag gtgtcattct attctggggg gtggggtggg	1086
aagggggagg attgggaaga caatagcagg catgctgggg atgcggtggg ctctatggcc	1146
tcgag	1151
<210>17	
<211>1849	
<212>DNA	
<213>Artificial sequence	
<220>	
<221>CDS	
<222>(1071)(1631)	
<221>sig_peptide	
<222>(1071)(1133)	
<221>mat_peptide	•
<222>(1134)(1631)	
<400>17	
ctcgagggtc agaaaccttg ttaaccaata gagccaaata tagttaacac aatagaaatt	60
tatecaaata ttattegtgt attgtttata geetttgtca agtettttae aaggeaagat	120
aataagtaat atteegtgat tggaegtaae attteeegga agateettag eegataagte	180
gaagageege atgtggetag agagaegegg gttteegace actggettag gegettatte	240
cgccataata gatgtacgtg ttcacaatta gcacccgaaa ttcgtaatag ctacgagaag	300
tategaatat caaaaateta tatattaata egtgaageaa aaaetttgta teeetttta	360
cgaaaattgc gaggacggag gagtatgaaa tttcccacac ttatagagaa tacagagaag	420
aagtgcacaa tgctaatatt tttttaaaat aatgcataaa agatacttta aatcaataaa	480
gaaaacagca cacacactac ataccatgta tttgacgcac acacgcatgt atactattta	540
ttgtcaaact tttgttcttg acgtctgtgt tcaaactgag aatagattaa atattgtttg	600
totttattaa tattttttaa tagtgtagto ttggcgaaat ttgtgattat agaagtataa	660
aatacaatca taatagtgta caaacttaca attoccaatt aattatagto gaatttogac	720
tactgoggga cototagtat taataattot otttaaaaaa aaacagagca toaaatactg	780

tos	C227	+~+			+ ~ +	~~~	~~~		~~~+	+	4			·		n		
															taacat	840		
															acaata	900		
															gtaagc	960		
												ccactttggc atagtcgtct						
			tete													1070		
			aag													1118		
	Thr	Asn	Lys		Leu	Leu	Gln	Ile	Ala	Leu	Leu	Leu	Cys	Phe	Ser			
1				5					10					. 15				
			ctt												-	1166		
Thr	Thr	Ala	Leu	Ser	Met	Ser	Tyr	Asn	Leu	Leu	Gly	Phe	Leu	Gln	Arg			
			20					25					30					
			ttt													1214		
Ser	Ser	Asn	Phe	Gln	Cys	Gln	Lys	Leu	Leu	Trp	Gln	Leu	Asn	Glÿ	Arg			
		35			•		40					45						
			tgc													1262		
Leu	Glu	Tyr	Cys	Leu	Lys	Asp	Arg	Met	Asn	Phe	Asp	Ile	Pro	Glu	Glu			
	50					55					60							
att	aag	cag	ctg	cag	cag	ttc	cag	aag	gag	gac	gcc	gca	ttg	acc	atc	1310		
Ile	Lys	Gln	Leu	Gln	Gln	Phe	Gln	Lys	Glu	Asp	Ala	Ala	Leu	Thr	Ile			
65					70					75					80			
tat	gag	atg	ctc	cag	aac	atc	ttt	gct	att	ttc	aga	caa	gat	tca	tat	1358		
Tyr	Glu	Met	Leu	Gln	Asn	Ile	Phe	Ala	Ile	Phe	Arg	Gln	Asp	Ser	Ser			
				85					90					95				
agc	act	ggc	tgg	aat	gag	act	att	gtt	gag	aac	ctc	ctg	gct	aat	gtc	1406		
Ser	Thr	Gly	Trp	Asn	Glu	Thr	Ile	Val	Glu	Asn	Leu	Leu	Ala	Asn	Val			
			100					105					110					
tat	cat	cag	ata	aac	cat	ctg	aag	aca	gtc	ctg	gaa	gaa	aaa	ctg	gag	1454		
Тут	His	Gln	Ile	Asn	His	Leu	Lys	Thr	Val	Leu	Glu	Glu	Lys	Leu	Glu			
		115					120		•			125 [.]						
aaa	gaa	gat	ttc	acc	agg	gga	aaa	ctc	atg	agc	agt	ctg	cac	ctg	aaa .	1502		
Lys	Glu	Asp	Phe	Thr	Arg	Gly	Lys	Leu	Met	Ser	Ser	Leu	His	Leu	Lys			
	130					135					140							
aga	tat	tat	ggg	agg	att	ctg	cat	tac	ctg	aag	gcc	aag	gag	tac	agt	1550		

Arg Tyr Tyr Gly Arg Ile Leu His Tyr Leu Lys Ala Lys Glu Tyr Ser													
145 150 155 160													
cac tgt gcc tgg acc ata gtc aga gtg gaa atc cta agg aac ttt tac	1598												
His Cys Ala Trp Thr Ile Val Arg Val Glu Ile Leu Arg Asn Phe Tyr													
165 170 175													
ttc att aac aga ctt aca ggt tac ctc cga aac tga cagecatetg	1644												
Phe Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn													
180 185													
ttgtttgccc ctcccccgtg ccttccttga ccctggaagg tgccactccc actgtccttt	1704												
cctaataaaa tgaggaaatt gcatcgcatt gtctgagtag gtgtcattct attctggggg													
gtggggtggg gcaggacagc aagggggagg attgggaaga caatagcagg catgctgggg	1824												
atgeggtggg ctctatggec tegag	1849												
<210>18													
<211>28													
<212>DNA													
<213>Artificial sequence													
<220>													
<223>Synthesized oligonucleotide													
<400>18													
acgcgtcgac atgaagctga ccgccctg	28												
<210>19													
<211>28													
<212>DNA													
<213>Artificial sequence													
<220>													
<223>Synthesized oligonucleotide													
<400>19													
ctagtctaga tcagggcttg gtgaagtg	28												
<210>20													
<211>1175													
<212>DNA													
<213>Artificial sequence													
<220>													

<221>	>CD	S														
<222	> (3	33)	((917)				•							
<221	>si	g_p	ept:	ide												
<222	> (3	33)	((401	.)											
<221	>ma	t_p	ept:	ide												
<222	> (4	02)	• • •	(917	')											
<400	>20															
ctcga	ggg	ga g	aaag	catg	a ag	taag	ttct	. tta	aata	tta	caaa	.aaaa	tt g	raacg	atatt	60
ataaa	att	ct t	taaa	atat	t aa	aagt	aaga	aca	ataa	gat	caat	taaa	tc a	taat	taatc	120
acatt	gtt	ca t	gate	acaa	t tt	aatt	tact	tca	tacg	ttg	tatt	gtta	itg t	taaa	taaaa	180
agatt	aat	tt c	tatg	taat	t gt	atct	gtac	aat	acaa	tgt	gtag	atgt	tt a	ttct	atcga	240
aagta	aat	ac g	tcaa	aact	c ga	aaat	tttc	agt	tataa	aaa	ggtt	caac	tt t	ttca	aatca	300
gcatc	agt	tc g	gtto	caac	t ct	caag	gte	g ac								332
atg a	ag	ctg	acc	gcc	ctg	cag	ctg	ctg	ctg	tgg	cac	agc	gca	ata	tgg	380
Met L	ys	Leu	Thr	Ala	Leu	Gln	Leu	Leu	Leu	Trp	His	Ser	Ala	Leu	Trp	
1				5					10					15		
atg g	_														,	428
Met V	al	Gln	Glu	Ala	Thr	Pro	Leu	Gly	Pro	Thr	Ser	Ser	Leu	Pro	Gln	
			20					25					30			
agc t																476
Ser F	he	Leu	Leu	Lys	Cys	Leu	Glu	Gln	Val	Arg	Lys		Gln	Ala	Asp	
• •		35					40				-	45				
ggc a		_														524
Gly T		Ala	Leụ	Gln	Glu		Leu	Cys	Ala	Ala		Lys	Leu	Cys	His	
	50					55					60					570
cat.g																572
Pro (Glu	Glu	Leu	Val		Leu	Gly	His	Ala		Gly	Ile	Pro	GIn		
65					70					75					80	600
ccc																620
Pro I	Leu	Ser	Ser		Ser	Ser	Gln	Ala		Gln	Leu	Thr	GTĀ		ren	
		•		85		_			90					95		669

Arg Gl	n Leu	His	Ser	Gly	Leu	Phe	Leu	Tyr	Gln	Gly	Leu	Leu	Gln	Ala	
		100					105					110			
ctg gc	a ggg	ata	tcc	ccc	gag	tta	gcc	ccc	acc	ctg	gac	atg	ctg	cag	716
Leu Al	a Gly	Ile	Ser	Pro	Glu	Leu	Ala	Pro	Thr	Leu	Asp	Met	Leu	Gln	
	115					120					125				
ctg ga	c atc	acc	gac	ttt	gct	atc	aac	atc	tgg	cag	cag	atg	gaa	gac	764
Leu As	p Ile	Thr	Asp	Phe	Ala	Ile	Asn	Ile	Trp	Gln	Gln	Met	Glu	Asp	
13	0				135					140					
gtg gg	g atg	gcc	cct	gca	gtg	ccg	acc	acc	cag	ggc	acc	atg	cca	acc	812
Val Gl	y Met	Ala	Pro	Ala	Val	Pro	Pro	Thr	Gln	Gly	Thr	Met	Pro	Thr	
145			,	150					155					160	
ttc ac	c tcg	gcc	ttc	cag	cgc	cgg	gca	gga	ggc	acc	ctg	gtt	gcc	taa	860
Phe Th	r Ser	Ala	Phe	Gln	Arg	Arg	Ala	Gly	Gly	Thr	Leu	Val	Ala	Ser	
			165					170		-			175		
aac ct	g cag	agc	ttc	ctg	gag	gtg	gca	tac	cgt	gct	ctg	cgc	cac	ttc	908
Asn Le	u Gln	Ser	Phe	Leu	Glu	Val	Ala	Tyr	Arg	Ala	Leu	Arg	His	Phe	
		180				. * *	185					190			
acc aa	g ccc	tga	tet	agac	ege 1	tgat	cago	st c	gact	gtgc	e tt	ctag	ttgc		960
Thr Ly	s Pro														*
	195				•						•				
cageca	tctg	ttgt	ttgc	cc c	tece	ccgt	g cc	ttcc	ttga	ccc	tgga	agg ·	tgec	actccc	1020
actgto	cttt	ccta	ataa	aa t	gagga	aaat	t gc	atcg	catt	gtc	tgag	tag (gtgt	cattct	1080
attctg	aaaa	gtgg	ggtg	gg g	cagg	acag	c aa	3 999	gagg	att	ggga	aga 🖟	caat	agcagg	1140
catget	gggg	atgo	ggtg	gg c	tcta	tggc	c to	gag							1175
<210>	21		•				•							•	
<211>	1873														
<212>	DNA														:
<213>	Arti	fici	al	seqı	ienc	e									
<220>								•						•	
<221>	CDS									•				•	
<222>	(107	1)	. (1	655)										
<221>	sig_	pept	ide												
<222>	(107	1)	.(1	139)										

14/23

<221>mat peptide

<222>(1140)...(1655) <400>21 ctcgagggtc agaaaccttg ttaaccaata gagccaaata tagttaacac aatagaaatt 60 tatccaaata ttattcgtgt attgtttata gcctttgtca agtcttttac aaggcaagat 120 aataagtaat attoogtgat tggaogtaac atttooogga agatoottag oogataagto 180 gaagagccgc atgtggctag agagacgcgg gtttccgacc actggcttag gcgcttattc 240 cgccataata gatgtacgtg ttcacaatta gcacccgaaa ttcgtaatag ctacgagaag 300 tatogaatat caaaaatota tatattaata ogtgaagcaa aaactttgta toocttttta 360 cgaaaattgc gaggacggag gagtatgaaa tttcccacac ttatagagaa tacagagaag 420 aagtgcacaa tgctaatatt tttttaaaat aatgcataaa agatacttta aatcaataaa 480 gaaaacagca cacacactac ataccatgta tttgacgcac acacgcatgt atactattta 540 ttgtcaaact tttgttcttg acgtctgtgt tcaaactgag aatagattaa atattgtttg 600 tetttattaa tatttttaa tagtgtagte ttggcgaaat ttgtgattat agaagtataa 660 aatacaatca taatagtgta caaacttaca attoccaatt aattatagto gaatttogac 720 tactgeggga cetetagtat taataattet etttaaaaaa aaacagagca teaaatactg 780 tcacaaatgt caagcgggtc tcaacgagcc atgaataaat tagaaatcaa ttaataacat 840 aaaataggca aacaaaataa aaccatttac atagagaacg tttgttgaac aaaaacaata 900 actigitatac attgittigca caaatgittig aaccgaaaat tiattactci ctacgtaage 960 ttgatcaaac ttcgttttcg tataaaacgc gttggcccaa ccactttggc atagtcgtct 1020 tatcatcggg tototaagga toaagggato caaagaccge caacgtcgac 1070 atg aag ctg acc gcc ctg cag ctg ctg tgg cac agc gca ctc tgg 1118 Met Lys Leu Thr Ala Leu Gln Leu Leu Trp His Ser Ala Leu Trp 1 atg gtg caa gaa gcc acc ccc ttg ggc cct acc age tcc ctg ccc cag 1166 Met Val Gln Glu Ala Thr Pro Leu Gly Pro Thr Ser Ser Leu Pro Gln age tte etg etc aag tge tta gaa caa gtg agg aag gte eag get gat 1214 Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys Val Gln Ala Asp ggc aca gcg ctg cag gag agg ctg tgc gcc gcc cac aag ctg tgc cac .1262 Gly Thr Ala Leu Gln Glu Arg Leu Cys Ala Ala His Lys Leu Cys His 50 55

15/23

cct	gag	gag	ctg	gtg	ctg	ctt	ggg	cac	gct	ctg	ggc	atc	ccc	cag	gct	1310
Pro	Glu	Glu	Leu	Val	Leu	Leu	Gly	His	Ala	Leu	Gly	Ile	Pro	Gln	Ala	
65					70				•	75					80	
ccc	ctg	agc	agc	tgc	tee	agc	cag	gcc	ctg	cag	ctg	acg	ggc	tgc	ctg	1358
Pro	Leu	Ser	Ser	Cys	Ser	Ser	Gln	Ala	Leu	Gln	Leu	Thr	Gly	Cys	Leu	
				85					90					. 95		
cgt	caa	ctc	cac	agt	ggc	ctc	ttc	ctc	tac	cag	ggc	ctc	ctg	cag	gcc	1406
Arg	Gln	Leu	His	Ser	Gly	Leu	Phe	Leu	Tyr	Gln	Gly	Leu	Leu	Gln	Ala	
			100					105					110			
ctg	gca	ggg	ata	tcc	ccc	gag	tta	gcc	ccc	acc	ctg	gac	atg	ctg	cag	1454
Leu	Ala	Gly	İle	Ser	Pro	Glu	Leu	Ala	Pro	Thr	Leu	Asp	Met	Leu	Gln	
		115					120					125				
ctg	gac	atc	acc	gac	ttt	gat	atc	aac	atc	tgg	cag	cag	atg	gaa	gac	1502
Leu	Asp	Ile	Thr	Asp	Phe	Ala	Ile	Asn	Ile	Trp	Gln	Gln	Met	Glu	Asp	
	130					135					140					
gtg	ggg	atg	gac	cct	gca	gtg	ccg	ccc	acc	cag	ggc	acc	atg	cca	acc	1550
Val	$\mathtt{Gl}_{\mathbf{Y}}$	Met	Ala	Pro	Ala	Val	Pro	Pro	Thr	Gln	Gly	Thr	Met	Pro	Thr	
145					150					155					160	
ttc	acc	tcg	gcc	ttc	cag	cgc	cgg	gca	gga	ggc	acc	ctg	gtt	gcc	tcc	1598
Phe	Thr	Ser	Ala	Phe	Gln	Arg	Arg	Ala	Gly	Gly	Thr	Leu	Val	Ala	Ser	
•				165					170					175		
aac	ctg	cag	agc	ttc	ctg	gag	gtg	gca	tac	cgt	gct	ctg	cgc	cac	ttc	1646
Asn	Leu	Gln	Ser	Phe	Leu	Glu	Val	Ala	Tyr	Arg	Ala	Leu	Arg	His	Pḥe	
			180					185					190			
acc	aag	ccc	tga	cago	ccato	etg 1	ttgti	ttgc	ca e1	tecc	ccgt	g cc	ttee	ttga		1698
Thr	Lys	Pro														
		195														
ecci	tggaa	agg	tgdc	actc	cc a	ctgt	cctti	t cci	taata	aaaa	tgaç	ggaaa	att	gcat	gcatt	1758
gta	tgagt	tag	gtgt	catt	ct at	ttet	1 9999	ggt	3 3 33.	tggg	gcag	ggaca	agc :	aagg	ggagg	1818
att	ggaa	aga (caata	agca	gg ca	atge	tgggg	g ato	gegg	ggg	ctc	tatg	gcc '	toġa	3	1873
<21	0>2	2														
<21	1>1	396														
<21	2>D	NA														

16/23

<213>Bomb	yx mori					
<400>22	•		•		•	
gggagaaagc	atgaagtaag	ttctttaaat	attacaaaaa	aattgaacga	tattataaaa	60
ttctttaaaa	tattaaaagt	aagaacaata	agatcaatta	aatcataatt	aatcacattg	120
ttcatgatca	caatttaatt	tacttcatac	gttgtattgt	tatgttaaat	aaaaagatta	180
atttctatgt	aattgtatct	gtacaataca	atgtgtagat	gtttattcta	tcgaaagtaa	240
atacgtcaaa	actcgaaaat	tttcagtata	aaaaggttca	actttttcaa	atcagcatca	300
gttcggttcc	aactctcaag	atgagagtca	aaacctttgt	gatcttgtgc	tgcgctctgc	360
aggtgagtta	attattttac	tattatttca	gaaggtggcc	agacgatatc	acgggccacc	420
tgataataag	tggtcgccaa	aacgcacaga	tatcgtaaat	tgtgccattt	gatttgtcac	480
geeegggggg	gctacggaat	aaactacatt	tatttattta	aaaaatgaac	cttagattat	540
gtaacttgtg	atttatttgc	gtcaaaagta	ggcaagatga	atctatgtaa	atacctgggc	600
agaettgeaa	tatcctattt	caccggtaaa	tcagcattgc	aatatgcaat	gcatattcaa	660
caatatgtaa	aacaattcgt	aaagcatcat	tagaaaatag	acgaaagaaa	ttgcataaaa	720
ttataaccgc	attattaatt	tattatgata	tctattaaca	attgctattg	ccttttttc	780
gcaaattata	atcattttca	taacctcgag	gtagcattct	gttacatttt	aatacattgg	840
tatgtgatta	taacacgagc	tgcccactga	gtttctcgcc	agatettete	agtgggtcgc	900
gttaccgatc	acgtgataga	ttctatgaag	cactgctctt	gttagggcta	gtgttagcaa	960
attetttcag	gttgagtctg	agageteace	tacccatcgg	agegtagetg	gaataggcta	1020
ccagctaata	ggtagggaaa	acaaagctcg	aaacaagctc	aagtaataac	aacataatgt	1080
gaccataaaa	tctcgtggtg	tatgagatac	aattatgtac	tttcccacaa	atgtttacat	1140
aattagaatg	ttgttcaact	tgcctaacgc	cccagctaga	acattcaatt	attactatta	1200
ccactactaa	ggcagtatgt	cctaactcgt	tccagatcag	cgctaacttc	gattgaatgt	1260
gcgaaattta	tagçtcaata	ttttagcact	tatcgtattg	atttaagaaa	aaattgttaa	1320
cattttgttt	cagtatgtcg	cttatacaaa	tgcaaacatc	aatgattttg	atgaggacta	1380
ttttgggagt	gatgtc					1396
<210>23			÷			
<211>6070)	•				
<212>DNA						
<213>Bomb	yx mori	-				
<400>23						
tcaagacatc	cttgattaag	gcagctgccg	atattgacat	ggacctcgtt	cgtgctgcga	60

tagacgactg gccgcgcaga ttgaaggcct gtattcaaaa tcacggaggt cattttgaat

aaactttagt gtcataagaa tctatgtttt gttaagttca ttttggtata tgaatggtta 180 cataatgaat aaacttgttt caattatttt acattaaaca tgtgacagaa tttatgacct 240 gactaggtag gtacaaacag cetttttgat attagaaaac taagtaaaat ageetaeggt 300 cacatetett teegtgggtg tegttaaagg gegaettaga gaaceaceaa gaacgtagea 360 gaatoctcag agtgtcatac cagcatacag ccatcgctaa ctgctattta ctggtaatag 420 ggcacattgt aatctcactt aaccatactg togggccacc atctagccta tttctgccac 480 gaatcaatcg tgagtgatgg acatagagaa actattagtt gagaagaaaa caagagcact 540 aaaggtttga tattgacaaa aatctacttc gccgtcactc cataggttta ttgtctctca 600 ttagtccaga acagcagtta cagacgtaag cttttacgca caaactacag ggttgctctt 660 tattgtatcg aaaatatggg acctgaataa gggcgatttt gacgcgtcct gcccgcccat 720 tecegatest aeggacagaa tggcaageag tegaegtege eecaaacaeg teatttegga 780 tecteacgat ecactaacgg tgetttaggt accteaagea eeggteateg ttetegtegg 840 accegteget tgegacgaag ggetegacga geaaattaae eeteagacae ageecaetga 900 gtttetegee ggatettete agegggtege gttteegate eggtggtaga ttetgegaag 960 cacggetett getaggatte gtgttagcaa egtegteagg tttgageece gtgageteae 1200 ttactagtta aggttacgct gaaatagcct ctcaaggctc tcagctaggt aggaaacaaa 1080 aaaaaaagtc ctgcccttaa caccgttgcg atggcttgtc ttctgcagcg tactgtcgtg gcagggcggt accgcaccat ctttttcgac gccaccttgt gatctgaagg cgaagatact 1200 cgaccttaat gattgaggca agagcgtaat acctcgcgct ccctagacga gtagatctcg 1260 tggaagattc ggcacacggc acacaaaaat agcttttgag atagccttca atgtaattat 1320 gtttttatat atatttacta gctgacccgg caaacgttgt gttgccttaa ataagatttc 1380 tagggaaatt ctagtgtaga aaaataacct cattcaacca cataatacct cattataacc 1440 aaaaaaaaat aatatccaaa aaataaaaat ataaaataaa tgtttggggt ggacaaccct 1500 tatcacatag gggtatgaaa attagatagt agecgattet cagacetaet gaacatacta 1560 ttgatacaca aataaaacca aaaaaacatg gctgaaaaat gtatagtagg tattgtatta 1620. ttaagtgtat aatctatgat gtatatgagt aagtaagaca ggagaccggc ttcgtcctca teegteataa aaacegteat aaaaateaaa eeegcaaaat tataatttge gtaattaetg 1740 gtggctggtg gtaggacett cttgtgagte egegegggta ggtaccacca tctgactatt 1800 ctgccgtgaa gcagtaatgg gtttcggttt gaagggcggg acagccgttg taactatact 1860 tgagacctta gaacttatat ctcaatgtgg gtggcgcatt tttttacggt aggcagcggc 1920 ttggctctgc ccctggcatt gctgaagtcc ataggcgacg gttaccactc accatcaggt 1980 gggccgtatg gccgtctgcc tacaaaatca ataaaaaaa aataaaaaat ttacgttgta 2040 gatgtctatg ggctccagta accacttaac accaggeggg ctgtgagete gtccaeceat 2100

ctaagcaata aaaataaata aatagatagt tgatcagtag tggaccggcg agggcgggag 2160 atcaaattga atttaaaata aaacataatt aaaggaattt gaaactataa actctgaata ataatttatc qtactacaat tataatattt gattgccatc ttgcaacctt attgcggatc 2280 2340 tgtgaataga aaaaaaaaa aaatcgggat ggaaaaatag gggttgatcg tataagagtg aaaattgaga gtaatatgga atttttttat tttaagtcat gacaaaataa aaataagatc 2400 ttgccaaaaa aatttaagtt tattattaaa ttaagtttaa caaataaaaa attggggttg 2460 2520 atcgcagagg ggtgaaaatt tagggtttta tgtatttttg tatgctgtat cataaaaaaa 2580 taaaaacaaa aaataaaaat agggggatga aaaataaatg ttgttcgatt ctcaaccctg geogatatge aegetaagat teacaaaaat eggtegagee gttteggagg agtteaatea 2640 2700 cgcaccccgt cacacgagaa ttttatttat tagatttaga agagctgaaa gataaatcga tatttaattt tgtaagttgt cttgatgata cattttttcg tttgtcattc tttcctgcag 2760 taataaatat ttactaacaa tcacgctacg ttaactggtc ccgtgataag ttcgtaaaga 2880 acttgtgtta caggtaccag ataacggata taaatgtaag atttttatta tacacataca 2940 tatatttcat atacattcat aaccctggaa aatacattta tatttatcat acaaatatct 3000 tecettggcg ggattegaac cegegacccc cttgtgtagt gacaatgtca cttaccacta caccetetgg cattgetggg cgacggtaac cacceaccat taggtgggcc atatgetegt 3120 ctgcctacaa gggaaataaa aaaaatatcc taatataaat tgcattaatt tttttaaacc 3180 qactttcaat cacaatqaaq acaqattctc gtcgaagttt gtttttgaaa ctatatcaat 3240 aacttttcat tatccgttct tcgtcttttg tcttttttc gcaaacaaaa cgaacaaaac 3300 gttctaattc gaaagatgtt ttgtacggaa agtttgaata agtgcttaat tgcaagtaac 3360 gtaacaatgt tttagggttc ggtcctcaat aaattcgacc aataaaccat acaaattctt 3420 3480 taacattttt ttaatettat aetagetgae eeggeagaet tegtggtgee teaategata 3540 aataaaatac ctatgcttct gtataaaata aacataaaac aaacaaaagg aatccgtccg acqqqaqaca catcaaaqqa aaaacatett ttttattttt ttacetttta aaccttetet 3600 qqacttccac aaataattta agaccaaaat tagccaaatc ggtctagcat tttcgagttt 3660 tagogagact aacgaacage aattcatttt tatatacaca gatttatgtt accggggtot 3720 agtgacctaa acgacttcag ctctaacact aggctaactc aggcttagta gcctggtcct 3780 agtgttagat ttgaagtcgt ctaatgcaaa gattattgga tctgatggat ccgtaaggac 3840 gtgtctagag cgtcgacggt gactagctcc tgcgtgatca ggaaaaatgt ggaaagctta 3900 3960 acgattttgt cacattttac ttatcacaac ttgtttttat aataattcgc ttaaatgagc 4020 agctattact taatctcgta gtggtttttg acaaaatcag cttctttaga actaaaatat catttttttc gtaatttttt taatgaaaaa tgctctagtg ttataccttt ccaaaatcac 4080

cattaattag	gtagtgttta	agcttgttgt	acaaaactgc	cacacgcatt	tttttctcca	4140
ctgtaggttg	tagttacgcg	aaaacaaaat	cgttctgtga	aaattcaaac	aaaaatattt	4200
tttcgtaaaa	acacttatca	atgagtaaag	taacaattca	tgaataattt	catgtaaaaa	4260
aaaaatacta	gaaaaggaat	ttttcattac	gagatgctta	aaaatctgtt	tcaaggtaga	4320
gatttttcga	tatttcggaa	aattttgtaa	aactgtaaat	ccgtaaaatt	ttgctaaaca	4380
tatattgtgt	tgttttggta	agtattgacc	caagctatca	cctcctgcag	tatgtcgtgc	4440
taattactgg	acacattgta	taacagttcc	actgtattga	caataataaa	acctcttcat	4500
tgacttgaga	atgtctggac	agatttggct	ttgtattttt	gatttacaaa	tgttttttg	4560
gtgatttacc	catccaaggc	attctccagg	atggttgtgg	catcacgccg	attggcaaac	4620
aaaaactaaa	atgaaactaa	aaagaaacag	tttccgctgt	cccgttcctc	tagtgggaga	4680
aagcatgaag	taagttcttt	aaatattaca	aaaaaattga	acgatattat	aaaattettt	4740
aaaatattaa	aagtaagaac	aataagatca	attaaatcat	aattaatcac	attgttcatg	4800
atcacaattt	aatttacttc	atacgttgta	ttgttatgtt	aaataaaaag	attaatttct	4860
atgtaattgt	atctgtacaa	tacaatgtgt	agatgtttat	tctatcgaaa	gtaaatacgt	4920
caaaactcga	aaattttcag	tataaaaagg	ttcaactttt	tcaaatcagc	atcagttcgg	4980
ttccaactct	caagatgaga	gtcaaaacct	ttýtgatett	gtgctgcgct	ctgcaggtga	5040
gttaattatt	ttactattat	ttcagaaggt	ggccagacga	tatcacgggc	cacctgataa	5100
taagtggtcg	ccaaaacgca	cagatatcgt	aaattgtgcc	atttgatttg	teacgcccgg	5160
gggggctacg	gaataaacta	catttattta	tttaaaaaat	gaaccttaga	ttatgtaact	5220
tgtgatttat	ttgcgtcaaa	agtaggcaag	atgaatctat	gtaaatacct	gggcagactt	5280
gcaatatcct	atttcaccgg	taaatcagca	ttgcaatatg	caatgcatat	tcaacaatat	5340
gtaaaacaat	togtaaagca	tcattagaaa	atagacgaaa	gaaattgcat	aaaattataa	5400
ccgcattatt	aatttattat	gatatctatt	aacaattgct	attgcctttt	tttcgcaaat	5460
tataatcatt	ttcataacct	cgaggtagca	ttctgttaca	ttttaataca	ttggtatgtg	5520
attataacac	gagetgeeca	ctgagtttct	cgccagatct	tctcagtggg	togogttacc	5580
gatcacgtga	tagattctat	gaagcactgc	tcttgttagg	gctagtgtta	gcaaattctt	5640
tcaggttgag	tctgagagct	cacctaccca	tcggagcgta	gctggaatag	gctaccagct	5700
aataggtagg	gaaaacaaag	ctcgaaacaa	gctcaagtaa	taacaacata	atgtgaccat	5760
aaaatctcgt	ggtgtatgag	atacaattat	gtactttccc	acaaatgttt	acataattag	5820
aatgttgttc	aacttgccta	acgccccagc	tagaacattc	aattattact	attaccacta	5880
ctaaggcagt	atgtcctaac	togttocaga	tcagcgctaa	cttcgattga	atgtgcgaaa	5940
tttatagete	aatattttag	cacttatcgt	attgatttaa	gaaaaaattg	ttaacatttt	6000
gtttcagtat	gtcgcttata	caaatgcaaa	catcaatgat	tttgatgagg	actattttgg	6060

gagtgatgtc	•		6070
<210>24	•		
<211>99			
<212>DNA			
<213>Bombyż mori			
<400>24			
cgcagttacg actattctcg tcgtaacgtc cgcaas	aact gtggaatte	tagaagacaa	60
ctagttgtta aattcagagc actgccttgt gtgaa	tga:		99
<210>25		•	
<211>28			•
<212>DNA			
<213>Artificial sequence			
<400>25			
ggcgcgccgg gagaaagcat gaagtaag			28
<210>26			
<211>26			
<212>DNA	•		
<213>Artificial sequence			
<400>26			
gtcgaccttg agagttggaa ccgaac			26
<210>27			
<211>24	*	¥	
<212>DNA		•	
<213>Artificial sequence			
<400>27			
gtcgacatgg cgctgccctc ttcc			24
<210>28	•		
<211>26		٠	
<212>DNA			
<213>Artificial sequence			
<400>28			
tgtggatect ttetegetec ttaate			26
<210>29	•		•

<211>32	•
<212>DNA	
<213>Artificial sequence	
<400>29	
ggatcctaat ttttaatata aaataaccct tg	32
<210>30	
<211>35	
<212>DNA	
<213>Artificial sequence	
<400>30	
cttggcgcgc cacgacgtag acgtatagcc atcgg	35
<210>31	
<211>31	
<212>DNA	
<213>Artificial sequence	
<400>31	
cttgtcgacg acatcactcc caaaatagtc c	31
<210>32	
<211>33	
<212>DNA	4
<213>Artificial sequence	
<400>32	
gtcggatccc gcagttacga ctattctcgt cgt	33
<210>33	
<211>31	
<212>DNA	
<213>Artificial sequence	
<400>33	
cccaatttgg cgcgcctcaa gacatccttg a	31
<210>34	•
<211>27	
<212>DNA	
<213>Artificial sequence	

<400>34	
gaatgctacc tcgaggttat gaaaatg	27
<210>35	
<211>24	
<212>DNA	
<213>Artificial sequence	
<400>35	
aacctcgagg tagcattctg ttac	24
<210>36	
<211>26	
<212>DNA	
<213>Artificial sequence	
<400>36	•
ggtaccggcg cgccacgacg tagacg	26
<210>37	
<211>30	
<212>DNA	
<213>Artificial sequence	
<400>37	
gtcgacatgt cgtttacttt gaccaacaag	30
<210>38	
<211>30	
<212>DNA	
<213>Artificial sequence	
<400>38	
ggatcctttt tgacaccaga ccaactggta	33

CLAIMS

- 1. A process for producing recombinant cytokine comprising producing a gene recombinant silkworm that incorporates cytokine gene in its chromosomes, producing recombinant cytokine protein in the silk glands or cocoon and silk thread of the resulting gene recombinant silkworm, and recovering the cytokine from the silk glands or cocoon and silk thread.
- 2. A process for producing recombinant cytokine according to claim 1 wherein a cytokine gene coupled downstream from a promoter specifically expressed in silk glands is incorporated in a chromosome.
- 3. A process for producing recombinant cytokine according to claim 2 wherein the promoter specifically expressed in silk glands is a sericin gene promoter.
- 4. A process for producing recombinant cytokine according to claim 2 wherein the promoter specifically expressed in silk glands is a fibroin H chain gene promoter.
- 5. A process for producing recombinant cytokine according to any of claims 1 through 4 wherein cytokine gene is incorporated in silkworm chromosomes using DNA originating in a transposon.
- 6. A process for producing recombinant cytokine according to claim 5 wherein the cytokine gene is located between a pair of inverted terminal sequences originating in a transposon.
- 7. A process for producing recombinant cytokine according to claim 5 or 6 wherein the DNA originating in a transposon originates in an insect.
- 8. A process for producing recombinant cytokine according to claim 7 wherein the transposon originates in piggyBac transposon originating in a lepidopteron.
- 9. A process for producing recombinant cytokine according to any of claims 1 through 8 wherein the cytokine gene is interferon gene or colony stimulating factor gene.

5

10

15

20

25

30

- 10. A process for producing recombinant cytokine according to claim 9 wherein the interferon gene or colony stimulating factor gene is feline interferon- ω gene, human interferon- β gene or feline granulocyte colony stimulating factor gene.
- 11. A process for producing recombinant cytokine according to any of claims 1 through 3 wherein cytokine is extracted from cocoon and silk thread by using an aqueous solvent.
- 12. A gene recombinant silkworm in which a cytokine gene has been inserted into a chromosome and cytokine is produced in silk glands or cocoon and silk thread.
 - 13. A gene recombinant silkworm according to claim 12 wherein the cytokine gene inserted into a chromosome is an interferon gene or colony stimulating factor gene.
 - 14. A gene recombinant silkworm according to claim 13 wherein the interferon gene or colony stimulating factor gene inserted into a chromosome is feline interferon— ω gene, human interferon— β gene or feline granulocyte colony stimulating factor gene.
 - 15. A vector for inserting an exogenous gene into silkworm chromosomes in which a cytokine gene is coupled downstream from a promoter that is specifically expressed in silk glands.
- 16. A vector for inserting an exogenous gene into silkworm chromosomes according to claim 15 wherein the promoter is sericin gene promoter.
 - 17. A vector for inserting an exogenous gene into silkworm chromosomes according to claim 15 wherein the promoter is a fibroin H chain gene promoter.
 - 18. A vector for inserting an exogenous gene into silkworm chromosomes according to any of claims 15 through 17 wherein the cytokine gene is located between a pair of inverted terminal sequences originating in a transposon.
 - 19. A vector for inserting an exogenous gene into

10

15

20

25

30

silkworm chromosomes according to any of claims 15 through 18 wherein the cytokine gene is an interferon gene or a colony stimulating factor gene.

- 20. A vector for inserting an exogenous gene into silkworm chromosomes according to claim 19 wherein the interferon gene or colony stimulating factor gene is feline interferon- ω gene, human interferon- β gene or feline granulocyte colony stimulating factor gene.
- 21. A gene cassette for expressing an exogenous protein comprising (1) a promoter expressed in silk glands, and (2) a gene coupled downstream from (1) in which the 5' terminal portion of fibroin H chain gene is fused to the 5' side of an exogenous protein structural gene.
- 22. A gene cassette for expressing an exogenous protein comprising (1) a promoter expressed in silk glands, and (2) a gene coupled downstream from (1) in which the 3' terminal portion of fibroin H chain gene is fused to the 3' side of an exogenous protein structural gene not containing a stop codon, or a gene cassette for expressing an exogenous protein comprising (1) a promoter expressed in silk glands, and (2) a gene coupled downstream from (1) in which an exogenous protein structural gene is fused to the 3' side of the 3' terminal portion of fibroin H chain gene.
 - 23. A gene cassette for expressing an exogenous protein comprising (1) a promoter expressed in silk glands, and (2) a gene coupled downstream from (1) in which the 5' terminal portion of fibroin H chain gene is fused to the 5' side of an exogenous protein structural gene not containing a stop codon, and in which the 3' terminal portion of fibrin H chain gene is fused to the 3' side of the structural gene.
- 24. A gene cassette according to claim 21 or 23
 wherein the 5' terminal portion of the fibroin H chain gene contains a first exon, first intron and a portion of a second exon of fibroin H chain gene.

5

10

15

20

25

- 25. A gene cassette according to claim 24 wherein the portion where the first exon and second exon of the fibroin H chain gene are joined is a secretion signal gene region of fibroin H chain gene.
- 26. A gene cassette according to claim 25 wherein the promoter expressed in silk glands of (1) and the 5 terminal portion of fibroin H chain gene coupled downstream from (1) are the DNA shown in SEQ. ID No. 22 and SEQ. ID No. 23.
- 27. A gene cassette according to claim 22 or 23 wherein the 3 terminal portion of the fibroin H chain gene contains at least one codon that encodes cysteine.
- 28. A gene cassette according to claim 27 wherein the 3 terminal portion of the fibroin H chain gene is the DNA shown in SEQ. ID No. 24.
- 29. A gene cassette according to any of claims 21 through 28 wherein the promoter expressed in silk glands is at least one promoter selected from fibroin H chain gene promoter, fibroin L chain gene promoter and sericin gene promoter.
- 30. A gene cassette according to any of claims 21 through 29 wherein at least one poly A addition region selected from a poly A addition region of fibroin H chain gene, a poly A addition region of fibroin L chain gene and a poly A addition region of sericin gene is present downstream from a gene cassette for expressing an exogenous protein according to any of claims 21 through 29.
- 31. A gene cassette for inserting a gene into chromosomes of insect cells comprising inverted repetitive sequences of a pair of piggyBac transposons present on both sides of a gene cassette for expressing an exogenous protein according to any of claims 21 through 30.
- 32. An expression vector for insect cells that contains a gene cassette for expressing an exogenous protein according to any of claims 21 through 31.

5

10

15

20

25

- 33. A gene insertion vector for insect cells that contains a gene cassette for inserting a gene into chromosomes of insect cells according to claim 31.
- 34. A process for producing an exogenous protein comprising inserting a vector for insect cells according to claim 32 or 33 into insect cells.
- 35. A process for producing an exogenous protein according to claim 34 wherein the insect cells originate in a lepidopteron.
- 36. A process for producing an exogenous protein according to claim 35 wherein the insect cells originate in silkworm moths (Bombyx mori).
- 37. A process for producing an exogenous protein according to claim 36 wherein the insect cells are silk gland cells of silkworm moths (Bombyx mori).
- 38. A process for producing an exogenous protein comprising producing a recombinant silkworm in which a gene cassette for expressing an exogenous protein according to any of claims 21 through 31 is inserted into a chromosome using a gene insertion vector for insect cells according to claim 33 and the DNA transfer activity of piggyBac transposase, producing exogenous protein in the silk glands or cocoon and silk thread of the resulting recombinant silkworm, recovering the exogenous protein from the silk glands or silk and cocoon thread.
- 39. A process for producing an exogenous protein according to claim 38 wherein the recombinant silkworm, in which the gene cassette for expressing an exogenous protein has been inserted into a chromosome, is produced by simultaneously micro-injecting the gene insertion vector for insect cells and DNA or RNA that produces the piggyBac transposase into silkworm eggs.
- 40. A recombinant silkworm in which a gene cassette for expressing an exogenous protein according to any of claims 21 through 31 has been inserted into a chromosome, and which has the ability to produce the exogenous protein in silk glands or silk thread.

5

10


15

20

25

30

41. Silk thread containing an exogenous protein produced by a recombinant silkworm according to claim 40.




SerP:SERIGIN-1 GENE PROMOTER
IFN:FELINE INTERFERON-ω GENE
BGHpA:BOVINE GROWTH HORMONE POLY A
A3P:A3 PROMOTER

GFP: GREEN FLUORESCENCE PROTEIN

SV40pA:SV40 POLY A

ITR: INVERTED TERMINAL SEQUENCE

Fig.2



FibHP:FIBROIN H CHAIN GENE PROMOTER IFN:FELINE INTERFERON— ω GENE BGHpA:BOVINE GROWTH HORMONE POLY A


A3P: A3 PROMOTER

GFP: GREEN FLUORESCENCE PROTEIN


SV40pA:SV40 POLY A

ITR: INVERTED TERMINAL SEQUENCE


Fig.3





ITR: INVERTED TERMINAL SEQUENCE



M:MOLECULAR WEIGHT MARKER







7/19





Fig.9











Fig.11














Fig.17




Fig.18

